---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description. Covers Product description and Place of product in therapy. 297 evidence topics quoted from 146 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Investigational status

> “We have not submitted for, or obtained, regulatory approval for any product candidate, and it is possible that none of our product candidates will ever obtain regulatory approval.”
> “have no products approved for commercial sale and have not generated any revenue”

Source: [ORIC Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330631/oric-20260630.htm)

> “This presentation discusses our product candidates that are under preclinical or clinical study, and which have not yet been approved for marketing by the U.S. Food and Drug Administration.”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.1.1-2"></a>

##### Investigational new drug application

> “We filed and cleared an Investigational New Drug application (IND) with the Food and Drug Administration (FDA) for rinzimetostat in the fourth quarter of 2021.”
> “We completed a Phase 1b trial of rinzimetostat as a single-agent, in patients with advanced prostate cancer”

Source: [ORIC Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330631/oric-20260630.htm)

<a id="topic-2.1.1-3"></a>

##### Initiation of the Himalayas-1 Phase 3 trial

> “today announced the initiation of the Himalayas-1 global Phase 3 registrational trial in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone”
> “Following End-of-Phase 1 interactions with the FDA and other global health authorities, ORIC finalized the trial protocol and has initiated the Himalayas-1 global Phase 3 registrational trial.”

Source: [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/)

> “In July 2026, we announced that we initiated our first global Phase 3 registrational trial for rinzimetostat in combination with darolutamide, named Himalayas-1, in post-abiraterone mCRPC patients.”

Source: [ORIC Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330631/oric-20260630.htm)

<a id="topic-2.1.1-4"></a>

##### Himalayas-1 registry status and dates

| Registry field | Quoted record |
| --- | --- |
| Overall status | “Recruiting” |
| Study start (actual) | “2026-08-03” |
| Primary completion (estimated) | “2028-03” |
| Study completion (estimated) | “2030-09” |

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-2.1.1-5"></a>

##### License from Mirati Therapeutics

> “On August 3, 2020, the Company entered into a license agreement (Mirati License Agreement) with Mirati. Under the Mirati License Agreement, Mirati granted the Company a worldwide, exclusive, sublicensable, royalty-free license under Mirati’s rights to certain patents and patent applications directed to certain small molecule compounds that bind to and inhibit PRC2”

Source: [ORIC Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330631/oric-20260630.htm)

> “Mirati has developed highly selective allosteric inhibitors of PRC2, including a lead candidate now designated as ORIC-944”
> “ORIC is not subject to any future milestone or royalty payment obligations to Mirati.”

Source: [ORIC Pharmaceuticals (2020)](https://oricpharma.com/news/oric-pharmaceuticals-expands-precision-oncology-pipeline-with-exclusive-worldwide-license-to-highly-selective-allosteric-prc2-inhibitors-from-mirati-therapeutics/)

<a id="topic-2.1.1-6"></a>

##### Expedited program designations

No evidence found.

<a id="topic-2.1.1-7"></a>

##### Regulatory status

No evidence found.

<a id="topic-2.1.1-8"></a>

##### Launch

No evidence found.

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: ORIC Pharmaceuticals

> “ORIC will conduct and sponsor the Himalayas-1 trial and Bayer will provide their AR inhibitor, NUBEQA ® (darolutamide), at no cost for use in the trial in combination with rinzimetostat.”
> “This agreement does not grant Bayer any license, option, or other rights to rinzimetostat and ORIC retains full global development and commercial rights to rinzimetostat.”

Source: [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/)

<a id="topic-2.1.2.1-2"></a>

###### Proposed international nonproprietary name

> “rinzimetostatum”
> “2369769-29-7”

Source: [WHO Drug Information Proposed INN List 133 (2025)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl133.pdf)

<a id="topic-2.1.2.1-3"></a>

###### Recommended international nonproprietary name

> “Recommended INN: List 95”
> “rinzimetostatum”

Source: [WHO Drug Information Recommended INN List 95 (2026)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl95.pdf)

<a id="topic-2.1.2.1-4"></a>

###### Former company code ORIC-944

> “Rinzimetostat (formerly ORIC-944), an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm development (EED) subunit”

Source: [ORIC Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526064005/oric-20251231.htm)

<a id="topic-2.1.2.1-5"></a>

###### Synonyms and originator code MRTX2219

> “MRTX2219”
> “ORIC-944”
> “9X4NP88TGB”

Source: [National Cancer Institute Thesaurus](https://api-evsrest.nci.nih.gov/api/v1/concept/ncit/C188381?include=full)

<a id="topic-2.1.2.1-6"></a>

###### Therapeutic class

> “rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer”

Source: [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/)

<a id="topic-2.1.2.1-7"></a>

###### Brand name

No evidence found.

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Oral route in the Phase 1/1b registry record

> “Oral, once daily, continuous”
> “ORIC-944 dosed orally on a continuous daily dosing regimen in 28-day cycles”

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)

<a id="topic-2.1.2.2-2"></a>

###### Phase 3 dose in the Himalayas-1 registry record

> “400 mg once daily (QD)”

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-2.1.2.2-3"></a>

###### Pharmaceutical form and unit strengths

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### WHO functional classification

> “embryonic ectoderm development (EED) protein inhibitor, antineoplastic”

Source: [WHO Drug Information Proposed INN List 133 (2025)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl133.pdf)

<a id="topic-2.1.2.4-2"></a>

###### National Cancer Institute Thesaurus classification

> “EED Inhibitor”
> “An orally bioavailable allosteric inhibitor of polycomb repressive complex 2 (PRC2), with potential antineoplastic activity.”

Source: [National Cancer Institute Thesaurus](https://api-evsrest.nci.nih.gov/api/v1/concept/ncit/C188381?include=full)

<a id="topic-2.1.2.4-3"></a>

###### AHFS classification

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Investigated indication in the Himalayas-1 Phase 3 trial

> “A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination With Darolutamide Compared With ARPI or Docetaxel in Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate (Himalayas-1)”

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-2.1.2.5-2"></a>

###### Required prior abiraterone and excluded prior therapies

> “Progressive disease in the setting of surgical or medical castration with evidence of disease progression on treatment with abiraterone acetate in the mCSPC setting or first line mCRPC setting is required”
> “Prior treatment for prostate cancer at any stage with cytotoxic chemotherapy, radioligand therapy (ie, 177Lu -PSMA-617, radium-223), ARPIs including apalutamide, darolutamide, and enzalutamide”
> “Docetaxel treatment is allowed for mCSPC, as long as no signs of failure or disease progression occurred during treatment or within 3 months of treatment completion”

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-2.1.2.5-3"></a>

###### Labeled indications of darolutamide, the combination partner

> “NUBEQA is indicated for the treatment of adult patients with:”
> “non-metastatic castration resistant prostate cancer (nmCRPC)”
> “metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.1.2.5-4"></a>

###### Combination with apalutamide in the Phase 1b trial

> “Rinzimetostat is being evaluated in a Phase 1b dose optimization trial in combination with ERLEADA ® (apalutamide), Johnson & Johnson’s AR inhibitor, and NUBEQA ® (darolutamide), Bayer’s AR inhibitor, in patients with mCRPC.”
> “while we continue to evaluate rinzimetostat in additional indications in prostate cancer and beyond.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

> “600 mg, 800 mg and 1,200 mg QD of rinzimetostat in combination with 240 mg QD of apalutamide”

Source: [ORIC Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330631/oric-20260630.htm)

<a id="topic-2.1.2.5-5"></a>

###### Pipeline entry for a second Phase 3 trial with apalutamide

> “Himalayas-2”
> “Combination with apalutamide”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Allosteric inhibition of PRC2 through the EED subunit

> “Rinzimetostat is a potent and selective allosteric inhibitor of PRC2 with mechanism of action via binding the EED subunit that was designed to have superior drug properties compared to EZH2 inhibitors”
> “PRC2 is a histone methyltransferase complex consisting of three core subunits: EED, EZH2 or EZH1, and SUZ12 and plays a key role in gene regulation and transcriptional repression, in particular during embryonic development.”
> “EED is responsible for histone binding and activation of PRC2. Allosteric inhibition of EED impacts the assembly, stabilization, and activation of PRC2.”

Source: [ORIC Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526064005/oric-20251231.htm)

<a id="topic-2.1.2.6.1-2"></a>

###### Depletion of H3K27 trimethylation

> “Upon oral administration, rinzimetostat targets and binds to the regulatory embryonic ectoderm development (EED) subunit of PRC2. This prevents the methyltransferase activity of PRC2, spefifically the methylation of histone 3 at lysine27 (H3K27). This depletes H3K27 trimethylation (H3K27me3) and modulates the expression of target genes.”

Source: [National Cancer Institute Thesaurus](https://api-evsrest.nci.nih.gov/api/v1/concept/ncit/C188381?include=full)

<a id="topic-2.1.2.6.1-3"></a>

###### Company rationale for targeting EED rather than EZH2

> “PRC2 has two druggable subunits, EZH2, whose enzymatic function is the target of first-generation therapeutics, and EED, which next-generation therapeutics like rinzimetostat inhibit.”
> “First, preclinical studies show that EED inhibition is active against mutants in EZH2 that confer innate resistance to EZH2 inhibitors. Second, in a similar fashion, acquired mutations in EZH2 are sensitive to EED inhibition. Third, cells treated with EZH2 inhibitors are also able to activate EHZ1 in a compensatory bypass mechanism of resistance, yet those cells are sensitive to EED inhibition.”

Source: [ORIC Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526064005/oric-20251231.htm)

<a id="topic-2.1.2.6.1-4"></a>

###### Rationale for combination with androgen receptor pathway inhibition

> “PRC2 activity increases in prostate cancer and associates with lineage plasticity and resistance”
> “PRC2 inhibitors constrain this process by restricting lineage-escape programs and enforcing a luminal, AR-dependent cell state in preclinical studies”

Source: [Friedman et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Preclinical-Translational-Poster.pdf)

> “Combining rinzimetostat with darolutamide may limit tumor cell adaptation and prolong clinical benefit from continued androgen receptor pathway inhibition”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### H3K27me3 reduction in peripheral blood with single-agent dosing

> “There was robust target engagement, with maximal decrease (≥75%) in H3K27me3 in monocytes from peripheral blood samples at doses as low as 200 mg QD with low inter-patient variability.”

Source: [ORIC Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526064005/oric-20251231.htm)

<a id="topic-2.1.2.6.2-2"></a>

###### H3K27me3 reduction in combination with darolutamide

> “Rinzimetostat pharmacokinetic and pharmacodynamic data were highly consistent as a single agent and in combination with darolutamide, and supportive of dose optimization of 400 mg and 600 mg QD”
> “monotherapy activity measured in monocytes derived”
> “combination activity measured in granulocytes derived from PBMCs”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.1.2.6.2-3"></a>

###### Plasma cell-free DNA methylation in participants treated with single-agent rinzimetostat

> “Plasma cfDNA methylation profiling showed epigenetic shifts indicative of increased AR signaling after one treatment cycle in most patients assessed.”

Source: [ORIC Pharmaceuticals ESMO preclinical and translational data release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-presents-preclinical-and-translational-data-to-support-the-potential-of-rinzimetostat-to-enhance-sensitivity-to-androgen-receptor-inhibition-in-prostate-cancer-at-esmo-congr/)

> “Plasma samples were collected at first day of treatment and after 28 days of rinzimetostat dosing. Cell free DNA was sequenced for DNA methylation with the PredicineALERT panel.”

Source: [Friedman et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Preclinical-Translational-Poster.pdf)

<a id="topic-2.1.2.6.2-4"></a>

###### Paired tumor biopsies in participants treated with single-agent rinzimetostat

> “Paired tumor biopsies showed increased levels of luminal and AR-associated markers PSMA and KLK2.”

Source: [ORIC Pharmaceuticals ESMO preclinical and translational data release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-presents-preclinical-and-translational-data-to-support-the-potential-of-rinzimetostat-to-enhance-sensitivity-to-androgen-receptor-inhibition-in-prostate-cancer-at-esmo-congr/)

> “Tumor biopsies were collected at screening and after 2 cycles of treatment, with biopsy taken from prostate for patient 1 and lymph node for patient 2.”
> “KLK2 staining was not done for patient 2 due to depleted tissue.”

Source: [Friedman et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Preclinical-Translational-Poster.pdf)

<a id="topic-2.1.2.6.2-5"></a>

###### Preclinical synergy with androgen receptor pathway inhibitors

> “ORIC-944 synergizes with ARPI and extends progression-free survival in CRPC and CSPC models in vivo”

Source: [Daemen et al. (2025)](https://oricpharma.com/wp-content/uploads/2025/04/AACR2025_ORIC-944-poster_Final.pdf)

> “Synergistic cell viability effects are achieved when inhibiting PRC2 either with allosteric EED inhibition using ORIC-944 or EZH2 inhibition using mevrometostat.”

Source: [Yuen et al. (2025)](https://oricpharma.com/wp-content/uploads/2025/10/ENA2025_ORIC-944-ARi-CSPC-Poster.pdf)

> “Rinzimetostat in combination with ARPI darolutamide demonstrated antitumor activity across a breadth of in vivo models representing the prostate cancer continuum”

Source: [Pankov et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/08/Rinzimetostat_20AACR_20Poster_201.pdf)

<a id="topic-2.1.2.6.2-6"></a>

###### Preclinical chromatin and lineage effects

> “Rinzimetostat restored access to AR binding motifs and restricted accessibility at sites associated with lineage plasticity in preclinical prostate cancer models, supporting a mechanism that reinforces AR dependence and limits tumor adaptation.”
> “KLK2 and STEAP1 luminal markers increased following rinzimetostat treatment in preclinical studies.”

Source: [ORIC Pharmaceuticals ESMO preclinical and translational data release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-presents-preclinical-and-translational-data-to-support-the-potential-of-rinzimetostat-to-enhance-sensitivity-to-androgen-receptor-inhibition-in-prostate-cancer-at-esmo-congr/)

<a id="topic-2.1.2.6.2-7"></a>

###### Preclinical single-agent activity in an enzalutamide-resistant model

> “ORIC-944 demonstrates strong single agent activity in enzalutamide-resistant, AR-v7+ prostate cancer xenograft model, 22Rv1”

Source: [Daemen et al. (2021)](https://oricpharma.com/wp-content/uploads/2021/03/ORIC-944-AACR2021-Abstract1131-FINAL.pdf)

<a id="topic-2.1.2.6.2-8"></a>

###### Preclinical activity in EZH2 inhibitor-resistant settings

> “Prostate cancer cells that rapidly developed resistance to mevrometostat acquired a mutation in EZH2 against which rinzimetostat potency was maintained; no emergence of rinzimetostat-resistant cells was observed.”

Source: [ORIC Pharmaceuticals ESMO preclinical and translational data release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-presents-preclinical-and-translational-data-to-support-the-potential-of-rinzimetostat-to-enhance-sensitivity-to-androgen-receptor-inhibition-in-prostate-cancer-at-esmo-congr/)

> “Rinzimetostat retained antitumor activity in prostate cancer cells with overexpressed EZH1 in vitro, while potency was diminished for mevrometostat or tazemetostat.”

Source: [ORIC Pharmaceuticals AACR preclinical data release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-presents-preclinical-data-to-support-the-potential-of-rinzimetostat-across-prostate-cancer-and-in-emerging-resistance-settings-at-the-2026-american-association-for-cancer-re/)

<a id="topic-2.1.2.6.2-9"></a>

###### Nonclinical toxicology: hematologic tumorigenesis in rats

> “No hematologic tumorigenesis was observed in the rinzimetostat rat toxicology study, in contrast to rat tumorigenesis demonstrated with EZH2 inhibitor tazemetostat; these results are consistent with mouse genetic studies of PRC2 components and suggest the tumorigenesis risk may be elevated with selective EZH2 targeting.”

Source: [ORIC Pharmaceuticals ESMO preclinical and translational data release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-presents-preclinical-and-translational-data-to-support-the-potential-of-rinzimetostat-to-enhance-sensitivity-to-androgen-receptor-inhibition-in-prostate-cancer-at-esmo-congr/)

> “EED genetic deletion in mice did not induce hematologic malignancy, consistent with rinzimetostat 13-week rat GLP tox study demonstrating no tumorigenesis.”

Source: [Friedman et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Preclinical-Translational-Poster.pdf)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Clinical half-life as reported in January 2024

> “As of December 10, 2023, the initial Phase 1b monotherapy data for ORIC-944”
> “Potential best-in-class drug properties, including clinical half-life consistent with preclinical prediction of >10 hours, which is superior to other PRC2 inhibitors and supports QD dosing”

Source: [ORIC Pharmaceuticals initial phase 1b data release (2024)](https://oricpharma.com/news/oric-pharmaceuticals-provides-initial-phase-1b-data-for-oric-944-operational-highlights-for-2023-and-anticipated-upcoming-milestones/)

<a id="topic-2.1.2.6.3-2"></a>

###### Estimated half-life by single-agent dose level as reported in April 2024

| Single-agent dose level | Estimated half-life (hours) |
| --- | --- |
| Dose level 1 | “~17” |
| Dose level 2 | “~19” |
| Dose level 3 | “~18” |
| Dose level 4 | “~26” |
| Dose level 5 | “~20” |

Source: [Friedman (2024)](https://oricpharma.com/wp-content/uploads/2024/04/AACR2024_ORIC-944_NDoH.pdf)

> “Dose level 1 (100mg QD)”
> “Dose level 3 (400mg QD)”
> “Dose level 5 (900mg QD)”
> “Dose exploration continues with favorable plasma half-life of approximately 20 hours”
> “The t1/2 values at Cycle 2 Day 1 were roughly estimated with a terminal phase spanning less than 2 half-lives. Mean half-life is shown for each cohort of patients.”

Source: [Friedman (2024)](https://oricpharma.com/wp-content/uploads/2024/04/AACR2024_ORIC-944_NDoH.pdf)

<a id="topic-2.1.2.6.3-3"></a>

###### Clinical half-life as reported in February 2026

> “As of December 10, 2023, these data demonstrated potential best-in-class drug properties, including an approximate 20-hour clinical half-life and no signs of cytochrome P450 autoinduction that is seen with first-generation PRC2 inhibitors.”

Source: [ORIC Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526064005/oric-20251231.htm)

<a id="topic-2.1.2.6.3-4"></a>

###### Exposure by dose level

> “Increased exposure with dose level”
> “Low peak-to-trough may facilitate better efficacy and safety”

Source: [Friedman (2024)](https://oricpharma.com/wp-content/uploads/2024/04/AACR2024_ORIC-944_NDoH.pdf)

> “Increased exposure with dose, exceeding target Cmin for ~24h”
> “Mean total plasma concentration (nM) at steady state (Cycle 2 Day 1)”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.1.2.6.3-5"></a>

###### Absence of CYP autoinduction

> “No signs of CYP autoinduction that is seen with first-generation PRC2 inhibitors”

Source: [ORIC Pharmaceuticals initial phase 1b data release (2024)](https://oricpharma.com/news/oric-pharmaceuticals-provides-initial-phase-1b-data-for-oric-944-operational-highlights-for-2023-and-anticipated-upcoming-milestones/)

<a id="topic-2.1.2.6.3-6"></a>

###### Food effect with darolutamide

> “Rinzimetostat 400 mg QD plus darolutamide is currently being evaluated in a food effect cohort. Thus far, there does not appear to be a significant food effect, consistent with previous single agent studies.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

> “ORIC is currently evaluating the impact of food for rinzimetostat plus darolutamide on PK, PD, safety and efficacy”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.1.2.6.3-7"></a>

###### Preclinical solubility, oral bioavailability, and half-life

| Property | Rinzimetostat |
| --- | --- |
| Solubility | “11.7 mg/ml” |
| Mouse oral bioavailability | “64%” |
| Mouse half-life, oral | “3-5 hr PO” |
| Mouse half-life, intravenous | “2.5 hr IV” |
| Clinical half-life | “~20 hrs” |

Source: [Friedman et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Preclinical-Translational-Poster.pdf)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Himalayas-1 protocol: age, performance status, and organ function

> “Male patients aged ≥18 years”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

> “Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1”
> “Adequate organ function”

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-2.1.2.8-2"></a>

###### Himalayas-1 protocol exclusion: brain metastases

> “Known or suspected brain metastasis or active leptomeningeal disease”

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-2.1.2.8-3"></a>

###### Himalayas-1 protocol exclusion: cardiovascular disease, recent radiotherapy, and gastrointestinal disease

> “Clinically significant cardiovascular disease”
> “Radiotherapy within 2 weeks before randomization”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

> “Active inflammatory gastrointestinal disease, chronic diarrhea, or previous gastric resection or lap-band surgery are excluded”

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-2.1.2.8-4"></a>

###### Phase 1b protocol exclusion: cardiac disease

> “History of class III or IV congestive heart failure or severe non-ischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months”

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)

<a id="topic-2.1.2.8-5"></a>

###### Phase 1b protocol exclusion: viral infection

> “Known, symptomatic human immunodeficiency virus (HIV) infection”
> “Active symptomatic Hepatitis B or C infection; patients with well controlled disease are eligible”

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)

<a id="topic-2.1.2.8-6"></a>

###### Phase 1b protocol exclusion: malabsorption and central nervous system metastases

> “Active gastrointestinal disease (eg, Crohn's disease, ulcerative colitis, short gut syndrome, etc) or other malabsorption syndromes that would reasonably impact drug absorption per investigator judgement”
> “History or presence of CNS metastases, unless previously treated and stable”

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)

<a id="topic-2.1.2.8-7"></a>

###### Renal impairment: darolutamide, the combination partner

> “For patients with severe renal impairment (eGFR 15–29 mL/min/1.73 m2) not receiving hemodialysis, the recommended dosage of NUBEQA is 300 mg twice daily”
> “No dose reduction is needed for patients with mild or moderate renal impairment (eGFR 30-89 mL/min/1.73 m2). The effect of end stage renal disease (eGFR ≤15 mL/min/1.73 m2) on darolutamide pharmacokinetics is unknown.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.1.2.8-8"></a>

###### Hepatic impairment: darolutamide, the combination partner

> “For patients with moderate hepatic impairment (Child-Pugh Class B), the recommended dosage of NUBEQA is 300 mg twice daily”
> “No dose reduction is needed for patients with mild hepatic impairment. The effect of severe hepatic impairment (Child-Pugh C) on darolutamide pharmacokinetics is unknown.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.1.2.8-9"></a>

###### Geriatric use: darolutamide, the combination partner

> “Of the 954 patients who received NUBEQA in ARAMIS, 88% of patients were 65 years and over, and 49% were 75 years and over.”
> “No overall differences in safety or efficacy were observed between these patients and younger patients in both studies.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.1.2.8-10"></a>

###### Males of reproductive potential: darolutamide, the combination partner

> “Based on the mechanism of action, advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 1 week after the last dose of NUBEQA”
> “Based on animal studies, NUBEQA may impair fertility in males of reproductive potential”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Rinzimetostat

<a id="topic-2.1.2.9.1-1"></a>

###### Coadministration with darolutamide

> “no drug-drug interaction; half-life of ~20h supports QD dosing”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.1.2.9.1-2"></a>

###### Effects of other drugs on darolutamide, the combination partner

> “Concomitant use of NUBEQA with a combined P-gp and strong or moderate CYP3A4 inducer decreases darolutamide exposure which may decrease NUBEQA activity”
> “Avoid concomitant use of NUBEQA with combined P-gp and strong or moderate CYP3A4 inducers.”
> “Concomitant use of NUBEQA with a combined P-gp and strong CYP3A4 inhibitor increases darolutamide exposure”
> “Monitor patients more frequently for NUBEQA adverse reactions and modify NUBEQA dosage as needed”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.1.2.9.1-3"></a>

###### Darolutamide metabolism and clinical interaction studies

> “Darolutamide is primarily metabolized by CYP3A4, as well as by UGT1A9 and UGT1A1.”
> “Concomitant use of rifampicin (a combined P-gp and strong CYP3A4 inducer) decreased mean darolutamide AUC0-72 by 72% and Cmax by 52%.”
> “Itraconazole (a strong combined CYP3A4 and P-gp inhibitor) increased mean darolutamide AUC0-72 by 1.7- and Cmax by 1.4-fold.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Rinzimetostat on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### In vitro CYP inhibition and induction

| Assay | Enzymes | Result |
| --- | --- | --- |
| CYP inhibition | “CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4” | “IC50 >10 µM” |
| CYP induction | “CYP1A2, CYP2B6, CYP3A4 (1 µM)” | “<2X of vehicle control; <20% of positive control” |

Source: [Daemen et al. (2021)](https://oricpharma.com/wp-content/uploads/2021/03/ORIC-944-AACR2021-Abstract1131-FINAL.pdf)

> “ORIC-944 exhibits clean CYP profile in inhibition and induction studies”
> “Clean CYP profile eliminating CYP-mediated DDI risk”

Source: [Daemen et al. (2021)](https://oricpharma.com/wp-content/uploads/2021/03/ORIC-944-AACR2021-Abstract1131-FINAL.pdf)

> “CYPs analyzed are 1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4 for inhibition, and 1A2, 2B6 and 3A4 for induction assessments.”

Source: [Friedman et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Preclinical-Translational-Poster.pdf)

<a id="topic-2.1.2.9.2-2"></a>

###### Effects of darolutamide, the combination partner, on other drugs

> “NUBEQA is an inhibitor of BCRP transporter. Concomitant use of NUBEQA increases the AUC and Cmax of BCRP substrates”
> “Avoid concomitant use with drugs that are BCRP substrates where possible. If used together, monitor patients more frequently for adverse reactions, and consider dose reduction of the BCRP substrate drug.”
> “NUBEQA is an inhibitor of OATP1B1 and OATP1B3 transporters. Concomitant use of NUBEQA may increase the plasma concentrations of OATP1B1 or OATP1B3 substrates.”
> “Concomitant use of darolutamide increased the mean AUC and Cmax of rosuvastatin (BCRP, OATP1B1 and OATP1B3 substrate) by approximately 5-fold.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Recommended Phase 3 dose with darolutamide

> “18 patients were treated with 400 mg of rinzimetostat once daily and 15 patients were treated with 600 mg of rinzimetostat once daily, both in combination with the standard dose of darolutamide at 600 mg twice daily.”
> “Based on these findings 400 mg once daily in combination with darolutamide has been selected as the RP3D for rinzimetostat.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

> “Phase 1b dose-optimization data supported selection of rinzimetostat 400 mg once daily (QD) in combination with darolutamide 600 mg twice daily (BID) for evaluation in Himalayas-1”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="topic-2.1.2.10.1-2"></a>

###### Exposure-response analysis supporting dose selection

> “The analysis demonstrated that 400 mg and 600 mg once daily provided comparable efficacy. In contrast, the E-R analysis identified statistically significant relationships between higher drug exposure and toxicities as well as increased rates of treatment modifications, clearly favoring the 400 mg dose on the basis of safety.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

> “Exposure-response analyses were conducted using data across the entire rinzimetostat clinical dataset (single-agent and combination, n=113 patients)”
> “Analyses demonstrated no exposure-efficacy correlation; however, 400 mg QD was associated with lower toxicity and fewer dose modifications, supporting its selection as the RP3D in combination with darolutamide”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.1.2.10.1-3"></a>

###### Provisional doses with darolutamide and with apalutamide

> “provisional RP2Ds of rinzimetostat to be tested in combination with the approved doses of darolutamide and apalutamide in the dose optimization portion of the Phase 1b trial: 400 mg and 600 mg once daily of rinzimetostat in combination with 600 mg twice daily of darolutamide; and 600 mg, 800 mg and 1,200 mg once daily of rinzimetostat in combination with 240 mg once daily of apalutamide.”

Source: [ORIC Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526064005/oric-20251231.htm)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Oral continuous daily dosing in 28-day cycles

> “ORIC-944 dosed orally on a continuous daily dosing regimen in 28-day cycles”
> “Oral, once daily, continuous”

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)

<a id="topic-2.1.2.10.2-2"></a>

###### Administration with or without food in Himalayas-1

> “randomized 1:1 to receive the RP3D of 400 mg once daily rinzimetostat (with or without food) in combination with darolutamide”

Source: [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/)

> “Rinzimetostat is being studied in a food effect cohort to potentially enable dosing under fed conditions, consistent with darolutamide dosing”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Access through clinical trials before approval

> “Currently, before our investigational therapies are approved by regulatory authorities, they can be accessed only through participation in our clinical trials, that is, only by patients who meet the clinical trial criteria and are enrolled in a clinical trial.”

Source: [ORIC Pharmaceuticals expanded access policy](https://oricpharma.com/patients/)

<a id="topic-2.1.2.11-2"></a>

###### Expanded access policy

> “Requests for expanded access are evaluated on a case-by-case basis, and only when a request is submitted by a doctor.”
> “Patient enrollment in an ORIC-sponsored clinical trial is not possible because the patient does not meet the criteria for participation.”
> “ORIC will acknowledge receipt of an expanded access inquiry or a request from a licensed physician within five (5) business days of receipt.”
> “If a request to provide an investigational drug is granted by ORIC, the FDA must grant final approval before ORIC can supply the investigational product to the requesting physician.”
> “Unless otherwise approved, ORIC is not currently able to provide expanded access outside of the United States.”

Source: [ORIC Pharmaceuticals expanded access policy](https://oricpharma.com/patients/)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Darolutamide: class and labeled indications

> “NUBEQA is an androgen receptor inhibitor indicated for the treatment of adult patients with:”
> “non-metastatic castration-resistant prostate cancer (nmCRPC)”
> “metastatic castration-sensitive prostate cancer (mCSPC) in combination”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.1.2.12-2"></a>

###### Darolutamide: recommended dosage and concurrent androgen deprivation

> “The recommended dose of NUBEQA is 600 mg orally, twice daily, with food”
> “Patients receiving NUBEQA should also receive a gonadotropin-releasing hormone (GnRH) agonist or antagonist concurrently or have had a bilateral orchiectomy.”
> “Advise patients to swallow tablets whole with food.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.1.2.12-3"></a>

###### Darolutamide: dosage modification for adverse reactions

> “If a patient experiences a greater than or equal to Grade 3 or an intolerable adverse reaction, withhold NUBEQA or reduce dosage to 300 mg twice daily until symptoms improve.”
> “Dosage reduction below 300 mg twice daily is not recommended.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.1.2.12-4"></a>

###### Darolutamide: warnings and precautions

> “Ischemic Heart Disease: Optimize management of cardiovascular risk factors. Monitor for signs and symptoms of coronary artery disease. Discontinue NUBEQA for Grade 3-4 events.”
> “Seizure: Consider discontinuation of NUBEQA in patients who develop a seizure during treatment.”
> “Embryo-Fetal Toxicity: NUBEQA can cause fetal harm and loss of pregnancy.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.1.2.12-5"></a>

###### Darolutamide: dosage form and package

> “NUBEQA 300 mg tablets are available in bottles of 120 tablets.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.1.2.12-6"></a>

###### Darolutamide: wholesale acquisition cost filing with the California Department of Health Care Access and Information

| Field | Quoted record |
| --- | --- |
| Manufacturer name | “Bayer” |
| National drug code | “50419039501” |
| Drug product description | “Nubeqa 300 mg tab 120 count” |
| WAC effective date | “2026-01-01T00:00:00” |
| WAC increase amount (USD) | “847.20” |
| WAC after increase (USD) | “15100.80” |

Source: [California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22manufacturer_name%22%2C%22ndc%22%2C%22drug_prod_desc%22%2C%22wac_effective_date%22%2C%22wac_increase_amount%22%2C%22wac_after_increase%22%20FROM%20%22dda8a083-bc81-4f6d-b02f-935a2df70328%22%20WHERE%20%22drug_prod_desc%22%20LIKE%20%27Nubeqa%25%27)

<a id="topic-2.1.2.12-7"></a>

###### Darolutamide supply for Himalayas-1 under the Bayer agreement

> “Under the terms of the agreement, ORIC will conduct and sponsor the Himalayas-1 trial and Bayer will provide their AR inhibitor”
> “at no cost for use in the trial in combination with rinzimetostat. This agreement does not grant Bayer any license, option, or other rights to rinzimetostat and ORIC retains full global development and commercial rights to rinzimetostat.”

Source: [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/)

<a id="topic-2.1.2.12-8"></a>

###### Continued androgen deprivation therapy in the rinzimetostat trials

> “Must have undergone bilateral orchiectomy or be willing to continue GnRH analogue or antagonist to maintain castrate levels of testosterone”

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)

> “Progressive disease in the setting of surgical or medical castration with evidence of disease progression on treatment with abiraterone acetate in the mCSPC setting or first line mCRPC setting is required”

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Rinzimetostat on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### Bone density evaluation during androgen deprivation therapy: CMS645v9 and MIPS Quality ID 462

| Field | Quoted record |
| --- | --- |
| CMS eCQM ID | “CMS645v9” |
| MIPS Quality ID | “462” |
| Measure steward | “Oregon Urology” |
| Description | “Percentage of patients determined as having prostate cancer who are currently starting or undergoing androgen deprivation therapy (ADT), for an anticipated period of 12 months or greater and who receive an initial bone density evaluation. The bone density evaluation must be prior to the start of ADT or within 3 months of the start of ADT.” |

Source: [eCQI Resource Center CMS645v9 (2026)](https://ecqi.healthit.gov/ecqm/ec/2026/cms0645v9)

> “Patients with prostate cancer undergoing prolonged androgen deprivation therapy (ADT) incur bone loss at a rate higher than menopausal patients (Guise, 2007).”
> “Bone density screening should be performed at the start of Androgen Deprivation Therapy (ADT) for prostate cancer. It should also be performed every 2 years for the patient with continued ADT or for patients with known osteoporosis.”

Source: [eCQI Resource Center CMS645v9 specification (2026)](https://ecqi.healthit.gov/sites/default/files/ecqm/measures/CMS645-v9.0.000-QDM.html)

<a id="topic-2.1.2.13-2"></a>

###### Enhancing Oncology Model: prostate cancer episodes

> “The Enhancing Oncology Model (EOM) is a nationwide voluntary payment model that incentivizes oncology practices to deliver coordinated, high-quality, patient-centered care for Medicare beneficiaries receiving systemic chemotherapy for seven specific cancers: high-risk breast cancer, lung cancer, chronic leukemia, small intestine/colorectal, lymphoma, multiple myeloma, and high-risk prostate cancer.”
> “An episode begins when a Medicare beneficiary starts chemotherapy for breast cancer, chronic leukemia, small intestine/colorectal cancer, lung cancer, lymphoma, multiple myeloma, or prostate cancer.”
> “EOM rewards participants who perform well on cost and quality metrics with performance-based payments.”

Source: [CMS Enhancing Oncology Model](https://www.cms.gov/priorities/innovation/innovation-models/enhancing-oncology-model)

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Mevrometostat plus enzalutamide: randomized phase 1 dose expansion after abiraterone

> “Pts with mCRPC who received prior abiraterone, ≤1 prior chemotherapy in any setting, with evidence of progression per modified Prostate Cancer Working Group 3 criteria were included. Pts receiving ADT were randomized 1:1 to M (orally, 1250 mg BID on empty stomach) + E (160 mg QD) or E, stratified by prior chemotherapy.”
> “As of Sept 2, 2024,81 pts were included (M+E, n=41; E, n=40). Median (IQR) follow-up was 9.6 (3.1-14.5) mo.”
> “Median (95% CI) rPFS was 14.3 (7.5, not estimable) mo for M+E and 6.2 (4.1, 13.9) mo for E (hazard ratio 0.51; 90% CI 0.28, 0.95).”
> “Confirmed PSA50 (95% CI) was observed in 34.1% (20.1, 50.6) of pts for M+E and 15.4% (6.0, 31.3) for E.”
> “Most common treatment-emergent adverse events (TEAEs) were diarrhea (78.0%), decreased appetite (58.5%), and dysgeusia (58.5%) for M+E, and asthenic conditions (42.5%), nausea (25.0%), and anemia (22.5%) for E. Grade ≥3 TEAEs were observed in 53.7% of pts in M+E (most common diarrhea, neutropenia and sepsis) and 42.5% in E. There were no treatment-related deaths.”

Source: [Schweizer et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.LBA138)

<a id="topic-2.1.2.14-2"></a>

###### Mevrometostat plus enzalutamide: dose escalation after abiraterone or enzalutamide

> “As of November 2, 2023, 47 pts had received ≥1 dose of study treatment. Median (interquartile range) duration of follow up was 9.7 (2.0-22.8) months (mo).”
> “Median (95% CI) rPFS was 17.0 (6.3, not estimable [NE]) mo in the total population; 17.1 (6.2, NE) mo for pts who received prior A (without E) (n=12), and 11.7 (4.2, NE) mo for pts who received prior E (± A) (n=35).”
> “Adverse events (AEs) led to treatment discontinuation in 9 (19.1%) pts. The most common treatment-emergent AEs (TEAEs) considered related to M were diarrhea (42.6%), dysgeusia (42.6%), and anemia (36.2%). Grade ≥3 TEAEs considered related to M were reported in 17.0% of pts.”

Source: [Schweizer et al. (2024)](https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.5061)

<a id="topic-2.1.2.14-3"></a>

###### Mevrometostat 875 mg with food plus enzalutamide: safety and selection of the phase 3 dose

> “As of Nov 15, 2024, 29 pts received M at 875mg with food + E. Median (interquartile range [IQR]) duration of treatment was 5.5 (4.1–7.4) months.”
> “The most common TEAEs of any grade related to M were diarrhea (41.4%), thrombocytopenia (41.4%), and dysgeusia (37.9%). Serious TEAEs related to M were reported in 3 (10.3%) pts (anemia, ECG QT prolonged, and hemorrhagic enterocolitis), all were grade 3. There were no grade 4 TEAEs. TEAEs led to withdrawal from M in 4 (13.8%) pts.”
> “M 875 mg with food + E was selected as the recommended dose for pivotal phase 3 studies.”

Source: [Matsubara et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.5046)

<a id="topic-2.1.2.14-4"></a>

###### Mevrometostat 875 mg with food plus enzalutamide: efficacy after abiraterone, enzalutamide naive

> “As of September 1, 2025, 29 pts had received M 875 mg BID with food + E (2A, n=15; 2C, n=14).”
> “In 2A, 9 (60.0%) pts had received abiraterone and 9 (60%) pts had received E; in 2C, 14 (100%) pts received prior abiraterone and were E naive.”
> “median (90% CI) rPFS was 14.3 (2.0, not estimable [NE]) months in 2A and NE (6.2, NE) months in 2C. Confirmed PSA50 (95% CI) was observed in 6 (40.0%) (16.3, 67.7) pts in 2A and 6 (42.9%) (17.7, 71.1) pts in 2C.”
> “For 2A+2C combined, most common treatment-emergent AEs (TEAEs) were diarrhea (48.3%), thrombocytopenia (48.3%), and decreased appetite (44.8%). Grade ≥3 TEAEs were observed in 41.3% of pts (most common: thrombocytopenia, anemia, asthenic conditions, and hypokalemia). Grade ≥3 TEAEs considered related to M were reported in 31.0% pts.”

Source: [Matsubara et al. (2026)](https://ascopubs.org/doi/10.1200/JCO.2026.44.7_suppl.195)

<a id="topic-2.1.2.14-5"></a>

###### Mevrometostat plus enzalutamide: MEVPRO-1 and MEVPRO-2 phase 3 designs

> “MEVPRO-1 ( NCT06551324 ) is an open-label, phase III trial which will evaluate mevrometostat plus enzalutamide versus physician’s choice of either enzalutamide or docetaxel in patients with mCRPC who have progressed following ≥12 weeks of treatment with abiraterone.”
> “Randomization will be stratified by previous docetaxel in the metastatic castration-sensitive prostate cancer (mCSPC) setting, physician’s choice of comparator (prespecified prior to randomization and will remain consistent throughout the study), and presence of hepatic metastases.”
> “MEVPRO-2 ( NCT06629779 ) is a double-blind, placebo-controlled, phase III trial that will evaluate mevrometostat plus enzalutamide versus enzalutamide alone in adult patients with mCRPC who are treatment-naïve”
> “The primary efficacy endpoint for both MEVPRO-1 and MEVPRO-2 is rPFS per RECIST 1.1 (soft tissue) and PCWG3 (bone) assessed by BICR. OS (alpha protected) is a key secondary endpoint in both studies.”
> “There will be no interim analysis for the primary endpoint (rPFS).”

Source: [Shore et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13203012/)

<a id="topic-2.1.2.14-6"></a>

###### Mevrometostat plus enzalutamide: MEVPRO-1 enrollment and estimated primary completion

> “Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment.”
> “Active, not recruiting”
> “2027-02-28”

Source: [ClinicalTrials.gov NCT06551324](https://clinicaltrials.gov/study/NCT06551324)

<a id="topic-2.1.2.14-7"></a>

###### Mevrometostat plus enzalutamide: MEVPRO-3 in metastatic castration-sensitive disease

> “This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.”

Source: [ClinicalTrials.gov NCT07028853](https://clinicaltrials.gov/study/NCT07028853)

<a id="topic-2.1.2.14-8"></a>

###### Tazemetostat plus enzalutamide: CELLO-1 randomized phase 2 after abiraterone

> “For phase 2 randomized component (i.e, enzalutamide- containing treatment arms) of the study, previously progressed on abiraterone.”
> “The study was terminated early as Sponsor decided to discontinue the development of tazemetostat in metastatic castration resistant prostate cancer and the primary endpoint was not met for this study. There were no safety concerns.”

Source: [ClinicalTrials.gov NCT04179864](https://clinicaltrials.gov/study/NCT04179864)

| Outcome | Tazemetostat 1200 mg twice daily plus enzalutamide | Enzalutamide |
| --- | --- | --- |
| Participants analyzed | “41” | “40” |
| Median rPFS, months (95% CI) | “22.1” (“16.6” to “27.6”) | “11.1” (“5.7” to “16.5”) |
| Confirmed PSA50 response, % (95% CI) | “19.5” (“8.82” to “34.87”) | “15.0” (“5.71” to “29.84”) |

Source: [ClinicalTrials.gov NCT04179864 results](https://clinicaltrials.gov/study/NCT04179864?tab=results)

<a id="topic-2.1.2.14-9"></a>

###### Tazemetostat: market withdrawal for hematologic second primary malignancies

> “The U.S. Food and Drug Administration (FDA) is alerting patients and health care providers about the voluntary withdrawal of Tazverik (tazemetostat) tablets from the market due to an increased rate of hematologic second primary malignancies (SPMs)”
> “In this study, as of March 6, 2026, 18 out of 318 (5.7%) patients treated with Tazverik developed hematologic SPMs, compared to no reported events among patients in the control arm.”
> “Most participants who developed the new blood cancers were receiving Tazverik for 1-3 years. The SPMs started as early as 7.5 months after beginning treatment and occurred in some patients after stopping treatment.”

Source: [FDA Tazverik safety alert (2026)](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-alerts-health-care-providers-and-patients-about-increased-risk-new-blood-cancers-tazverik)

> “Dedicated carcinogenicity studies were not conducted with tazemetostat, but T-LBL, MDS, AML, and B-ALL have been reported clinically and T-LBL occurred in juvenile and adult rats after ~9 or more weeks of tazemetostat administration during 13-week toxicity studies.”

Source: [Tazverik prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211723s005lbl.pdf)

<a id="topic-2.1.2.14-10"></a>

###### Class concern for hematologic malignancy with chronic PRC2 inhibition in prostate cancer

> “Mevrometostat, valemetostat, and tulmimetostat ( 18 – 20 ) have now been evaluated in several hundred patients. To date, no comparable secondary-malignancy signal has been publicly reported for these agents. This experience is reassuring but not yet definitive.”
> “In the phase 1/2 mevrometostat experience, median follow-up was approximately 9.6 months as of the September 2, 2024 data cut ( 21 ) substantially shorter than the interval over which therapy-related MDS/AML typically emerge.”
> “All of these factors are possible mediators of risk, though no published data currently link any specific pharmacologic property to differential second-malignancy risk.”

Source: [Alumkal and Ellis (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13552191/)

<a id="topic-2.1.2.14-11"></a>

###### CPI-1205 plus enzalutamide or abiraterone: ProSTAR phase 1b/2

> “This was an open-label Phase 1b/2 study involving oral administration of CPI-1205 in combination with either enzalutamide or abiraterone/prednisone in male patients with metastatic Castration-Resistant Prostate Cancer.”

Source: [ClinicalTrials.gov NCT03480646](https://clinicaltrials.gov/study/NCT03480646)

| Outcome | CPI-1205 800 mg three times daily plus enzalutamide | Enzalutamide |
| --- | --- | --- |
| Best objective response rate, % (95% CI) | “7.89” (“1.66” to “21.38”) | “5.71” (“0.70” to “19.16”) |
| Composite response rate, % (95% CI) | “31.4” (“16.9” to “49.3”) | “17.1” (“6.6” to “33.6”) |

Source: [ClinicalTrials.gov NCT03480646 results](https://clinicaltrials.gov/study/NCT03480646?tab=results)

<a id="topic-2.1.2.14-12"></a>

###### Company benchmark comparison: landmark rPFS and safety versus mevrometostat after abiraterone

| Regimen | Median follow-up | Month 3 rPFS | Month 4 rPFS | Month 5 rPFS | Grade 3 or higher TRAEs | Dose reductions / discontinuations |
| --- | --- | --- | --- | --- | --- | --- |
| Mevrometostat 875 mg twice daily fed plus enzalutamide (n=14) | “9.2” months | “92%” | “92%” | “84%” | “36%” | “7% / 7%” |
| Mevrometostat 1250 mg twice daily fasted plus enzalutamide (n=41) | “11.7” months | “92%” | “86%” | “80%” | “49%” | “37% / 2%” |
| Enzalutamide monotherapy (n=40) | “9.0” months | “78%” | “70%” | “60%” | “23%” | “8% / 5%” |
| Rinzimetostat 400 mg once daily plus darolutamide (n=18) | “4.9” months | “93%” | “84%” | “84%” | “6%” | “None / 6%” |

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

> “Preliminary rinzimetostat rPFS landmark analysis, albeit early, compares favorably to competitor benchmarks with a far cleaner safety profile, despite more heavily pretreated patients”
> “Note: Competitor rPFS percentages estimated from published data.”
> “Cross-trial comparison in previously treated mCRPC patients shown.”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.1.2.14-13"></a>

###### Company benchmark comparison: serious adverse events and dose modifications versus mevrometostat

| Measure | Mevrometostat 875 mg twice daily fed plus enzalutamide (n=14) | Mevrometostat 1250 mg twice daily fasted plus enzalutamide (n=41) | Rinzimetostat 400 mg once daily plus darolutamide (n=18) |
| --- | --- | --- | --- |
| Grade 3 or higher TRAEs | “36%” | “49%” | “6%” |
| Serious TRAEs | “21%” | “24%” | “None” |
| Dose reductions | “7%” | “37%” | “None” |
| Treatment discontinuations | “7%” | “2%” | “6%” |

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.1.2.14-14"></a>

###### Company comparison of rPFS across post-ARPI therapies

| Treatment | Status | Month 5 rPFS | Median rPFS, months |
| --- | --- | --- | --- |
| Enzalutamide | “Approved” | “60%” | “6.2” |
| Cabazitaxel | “Approved” | “65%” | “8.0” |
| Docetaxel | “Approved” | “75%” | “8.3” |
| Lutetium Lu 177 vipivotide tetraxetan | “Approved” | “75%” | “9.3” |
| Mevrometostat plus enzalutamide | “Phase 3” | “80% to 84%” | “~12 to 14” |
| Rinzimetostat plus darolutamide | “Starting” “Phase 3” | “84% to 85%” | “Not mature” |

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

> “PRC2 inhibitors in combination with an AR inhibitor have demonstrated much longer rPFS (key regulatory primary endpoint) than what has been reported with other approved and emerging therapies”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.1.2.14-15"></a>

###### Company statements comparing dose optimization results with mevrometostat

> “The durability observed to date is consistent with the competitor PRC2 inhibitor currently in Phase 3 in mCRPC and appears meaningfully improved relative to other approved standard of care therapies.”
> “Notably, rinzimetostat demonstrated this impressive durability with a markedly cleaner safety profile than competitor regimens.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="topic-2.1.2.14-16"></a>

###### Company comparison of PRC2 inhibitor development status

| Product | Development status |
| --- | --- |
| CPI-1205 | “Discontinued” |
| Tazemetostat | “Discontinued” |
| Mevrometostat | “Phase 3 trials ongoing” |
| Rinzimetostat | “First Phase 3 initiation expected 1H 2026” |

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

> “Rinzimetostat is a potential best-in-class PRC2 inhibitor that addresses the limitations of earlier generation PRC2 inhibitors”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.1.2.14-17"></a>

###### Company preclinical claims for EED targeting: EZH1 coverage and acquired resistance

> “Differential potency of PRC2 inhibitors on EZH1- vs. EZH2-containing complexes impacts activity in resistance contexts, providing potential advantages for EED targeting. Rinzimetostat retained antitumor activity in prostate cancer cells with overexpressed EZH1 in vitro, while potency was diminished for mevrometostat or tazemetostat.”

Source: [ORIC Pharmaceuticals AACR preclinical data release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-presents-preclinical-data-to-support-the-potential-of-rinzimetostat-across-prostate-cancer-and-in-emerging-resistance-settings-at-the-2026-american-association-for-cancer-re/)

> “Prostate cancer cells that rapidly developed resistance to mevrometostat acquired a mutation in EZH2 against which rinzimetostat potency was maintained; no emergence of rinzimetostat-resistant cells was observed.”

Source: [ORIC Pharmaceuticals ESMO preclinical and translational data release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-presents-preclinical-and-translational-data-to-support-the-potential-of-rinzimetostat-to-enhance-sensitivity-to-androgen-receptor-inhibition-in-prostate-cancer-at-esmo-congr/)

<a id="topic-2.1.2.14-18"></a>

###### Company preclinical claims for hematologic tumorigenesis in rat toxicology versus tazemetostat

> “No hematologic tumorigenesis was observed in the rinzimetostat rat toxicology study, in contrast to rat tumorigenesis demonstrated with EZH2 inhibitor tazemetostat; these results are consistent with mouse genetic studies of PRC2 components and suggest the tumorigenesis risk may be elevated with selective EZH2 targeting.”

Source: [ORIC Pharmaceuticals ESMO preclinical and translational data release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-presents-preclinical-and-translational-data-to-support-the-potential-of-rinzimetostat-to-enhance-sensitivity-to-androgen-receptor-inhibition-in-prostate-cancer-at-esmo-congr/)

> “EZH2 genetic deletion in mice induced hematologic malignancies, consistent with tazemetostat results in 13-week rat GLP tox study demonstrating tumorigenesis. EED genetic deletion in mice did not induce hematologic malignancy, consistent with rinzimetostat 13-week rat GLP tox study demonstrating no tumorigenesis.”

Source: [Friedman et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Preclinical-Translational-Poster.pdf)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Definition of castration-resistant prostate cancer

> “Castrate serum testosterone < 50 ng/dL or 1.7 nmol/L plus either:”
> “Biochemical progression: Three consecutive rises in PSA at least one week apart resulting in two 50% increases over the nadir, and a PSA > 2 ng/mL.”
> “Radiological progression: The appearance of new lesions: either two or more new bone lesions on bone scan, ideally confirmed”
> “or a soft tissue lesion using RECIST (Response Evaluation Criteria in Solid Tumours)”
> “Symptomatic progression alone must be questioned and subject to further investigation. It is not sufficient to diagnose CRPC.”
> “Unequivocal clinical progression.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.1.1-2"></a>

###### Castrate testosterone threshold in clinical trials

> “PCWG3 retains the definition of castrate as ≤ 50 ng/dL of testosterone (or ≤ 0.50 ng/mL or 1.73 nmol/L) but encourages investigators to consider using ultrasensitive testosterone assays with a sensitivity to 1 to 2 ng/dL when evaluating a drug known or suspected to change androgen levels.”

Source: [Scher et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872347/)

<a id="topic-2.2.1.1-3"></a>

###### Clinical states model and lines of prior therapy

> “Considers mCRPC in terms of number of lines of prior therapy rather than in relation to docetaxel treatment”
> “replacing the pre- versus postchemotherapy distinction with a dynamic classification that considers the lines of therapy a patient has received independent of the mechanism of action, the order in which they were administered, and the sensitivity of the tumor to each”

Source: [Scher et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872347/)

<a id="topic-2.2.1.1-4"></a>

###### Etiology of castration resistance: continued androgen receptor signaling

> “It is now accepted that castration-resistant prostate cancer is not androgen-independent and continues to rely on androgen signaling.”

Source: [Antonarakis et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4201502/)

> “An abundance of data acquired since then, however, has made it overwhelmingly clear that residual androgens remaining after castration and AR itself remain central both to the progression to CRPC and to its continued growth.”

Source: [Watson et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4771416/)

<a id="topic-2.2.1.1-5"></a>

###### Progression from prostate cancer to castration resistance

> “Together, the data indicate that 10-20% of prostate cancer patients develop CRPC within approximately 5 years of follow-up.”
> “Together, ≥ 84% were shown to have metastases at diagnosis.”

Source: [Kirby et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21995694/)

<a id="topic-2.2.1.1-6"></a>

###### Risk factors for prostate cancer, all stages

> “Prostate cancer occurs only in men, and it is more common in older men than younger men. It is more likely to occur in men with a family history of prostate cancer and non-Hispanic Black men.”

Source: [National Cancer Institute SEER Cancer Stat Facts](https://seer.cancer.gov/statfacts/html/prost.html)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

<a id="topic-2.2.1.2.1-1"></a>

###### Estimated U.S. new cases in 2026, all prostate cancer stages

| Measure | Quoted value |
| --- | --- |
| Estimated new cases of prostate cancer, United States, 2026 | “333,830” |

Source: [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)

> “In 2026, it is estimated that there will be 333,830 new cases of prostate cancer and an estimated 36,320 people will die of this disease.”

Source: [National Cancer Institute SEER Cancer Stat Facts](https://seer.cancer.gov/statfacts/html/prost.html)

<a id="topic-2.2.1.2.1-2"></a>

###### U.S. incidence rate, all prostate cancer stages

> “The rate of new cases of prostate cancer was 123.2 per 100,000 men per year. The death rate was 18.9 per 100,000 men per year. These rates are age-adjusted and based on 2019–2023 cases and 2020–2024 deaths.”

Source: [National Cancer Institute SEER Cancer Stat Facts](https://seer.cancer.gov/statfacts/html/prost.html)

<a id="topic-2.2.1.2.1-3"></a>

###### Distant-stage disease at diagnosis, all prostate cancer

| SEER measure | Quoted value |
| --- | --- |
| Percentage of cases diagnosed at distant stage | “9%” |

Source: [National Cancer Institute SEER Cancer Stat Facts](https://seer.cancer.gov/statfacts/html/prost.html)

<a id="topic-2.2.1.2.1-4"></a>

###### U.S. incidence trend of regional-stage and distant-stage prostate cancer

> “From 2014 through 2022, the prostate cancer incidence rate rose by 2.9% per year (Table 5), with a longer and steeper slope for regional‐stage (4.6% per year since 2013) and distant‐stage (5.6% per year since 2011) disease.”

Source: [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)

<a id="topic-2.2.1.2.1-5"></a>

###### Modeled U.S. annual incidence of metastatic castration-resistant prostate cancer, 2009 and 2020

> “The model estimated the prevalence of prostate cancer as 2,219,280 in the US in 2009 and 3,072,480 in 2020, and incidence of mCRPC as 36,100 and 42,970, respectively.”
> “The majority (86%) of incidence flow into mCRPC states was from the nmCRPC clinical state.”

Source: [Scher et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4603789/)

<a id="topic-2.2.1.2.1-6"></a>

###### Newly diagnosed metastatic castration-resistant prostate cancer in Medicare fee-for-service, 2014 to 2019

> “Men newly diagnosed with mCRPC were identified in Medicare fee-for-service claims during 1/1/2014–6/30/2019.”
> “The final study population consisted of 14,780 men”

Source: [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/)

<a id="topic-2.2.1.2.1-7"></a>

###### Company estimate: U.S. annual incidence of metastatic castration-resistant prostate cancer after abiraterone

> “In the US, the annual incidence of mCRPC patients previously treated with abiraterone is approximately 17,000, with an estimated addressable market of greater than $3.5 billion and total global addressable market of $7 billion.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

<a id="topic-2.2.1.2.2-1"></a>

###### U.S. prevalence in 2023, all prostate cancer stages

> “In 2023, there were an estimated 3,700,086 men living with prostate cancer in the United States.”

Source: [National Cancer Institute SEER Cancer Stat Facts](https://seer.cancer.gov/statfacts/html/prost.html)

<a id="topic-2.2.1.2.2-2"></a>

###### Modeled U.S. prevalence of metastatic castration-resistant prostate cancer by clinical state, 2009 and 2020

| Clinical state | Prevalence, 2009 | Prevalence, 2020 projection |
| --- | --- | --- |
| Asymptomatic or minimally symptomatic mCRPC not treated with or not progressed on chemotherapy | “6745” | “8320” |
| Symptomatic mCRPC not treated with or not progressed on chemotherapy | “32,145” | “39,650” |
| mCRPC that progressed on or after first-line chemotherapy | “23,220” | “28,720” |

Source: [Scher et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4603789/)

<a id="topic-2.2.1.2.2-3"></a>

###### Metastatic disease among men living with prostate cancer, modeled U.S. estimate for 2009

> “Of these, 2,121,650 (95.6%) presented with localized or locally advanced disease while 97,630 (4.4%) had metastatic prostate cancer (corresponding to non-castrate and mCRPC states).”

Source: [Scher et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4603789/)

<a id="topic-2.2.1.2.2-4"></a>

###### Prior androgen receptor pathway inhibitor before metastatic castration-resistant prostate cancer, U.S. Flatiron cohort 2016 to 2023

> “Before mCRPC diagnosis, most patients (73.9% [3963/5361]) had not received treatment intensification; 867 (16.2%) had received prior ARPi only; 448 (8.4%), prior taxane only; and 83 (1.5%), both prior ARPi and taxane.”
> “The use of ARPi-only treatment before mCRPC diagnosis rose from 10.3% in 2018 to 34.8% in 2023.”
> “Over the study course, the majority (76.8%) of patients received an ARPi as 1L treatment for mCRPC.”

Source: [Swami et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42235146/)

<a id="topic-2.2.1.2.2-5"></a>

###### Prior abiraterone for metastatic hormone-sensitive disease and androgen receptor pathway inhibitor reuse, U.S. ConcertAI cohort 2020 to 2023

> “Among 609 people identified, the most common prior treatment for mHSPC was androgen deprivation therapy (ADT) alone (53%); others included ADT plus abiraterone (ABI; 19%), ADT plus a non-ABI androgen receptor pathway inhibitor (ARPI; 18%) and ADT plus docetaxel (10%).”
> “Among those who received ADT plus ABI or a non-ABI ARPI for mHSPC, 50% and 40%, respectively, also received an ARPI 1L for mCRPC.”

Source: [Raval et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40670254/)

<a id="topic-2.2.1.2.2-6"></a>

###### Prior novel hormonal therapy and sequential novel hormonal therapy, Medicare fee-for-service cohort 2014 to 2019

> “Ten per cent of patients had undergone NHT use prior to their mCRPC diagnosis, and 3% had previously been treated with taxane-based chemotherapy.”
> “The most common 1 L to 2 L treatment sequences among men with ≥2 lines were NHT followed by a different NHT (33%), chemotherapy followed by NHT (14%), and NHT followed by chemotherapy (13%).”

Source: [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/)

<a id="topic-2.2.1.2.2-7"></a>

###### Androgen receptor pathway inhibitor sequencing across real-world studies

> “ARPI-to-ARPI from the first to the second line was the most common sequence in the US studies.”

Source: [Raval et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41266184/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Progression to metastatic castration-resistant disease as the cause of prostate cancer death

> “Prostate cancer deaths are typically the result of progression to metastatic castration-resistant prostate cancer (mCRPC).”

Source: [AUA (2026)](https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer)

<a id="topic-2.2.1.3-2"></a>

###### Modeled share of U.S. prostate cancer deaths occurring in metastatic castration-resistant states

> “All-cause mortality in prostate cancer was estimated at 168,290 in 2009 and 219,360 in 2020, with 20.5% and 19.5% of these deaths, respectively, occurring in men with mCRPC.”

Source: [Scher et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4603789/)

<a id="topic-2.2.1.3-3"></a>

###### Estimated U.S. deaths in 2026, all prostate cancer stages

| Measure | Quoted value |
| --- | --- |
| Estimated deaths from prostate cancer, United States, 2026 | “36,320” |

Source: [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)

> “Prostate cancer is the second-leading cause of cancer death in men in the US, behind only lung cancer. About 1 in 49 men will die of prostate cancer.”

Source: [American Cancer Society (2026)](https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html)

<a id="topic-2.2.1.3-4"></a>

###### U.S. prostate cancer mortality trend, all stages

> “Increased incidence also may be contributing to a deceleration in the decline for prostate cancer mortality, from 3.5% per year during the late 1990s and 2000s to 0.6% per year from 2012 through 2023 (Table 8, Figure 5).”

Source: [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)

<a id="topic-2.2.1.3-5"></a>

###### Distant-stage five-year relative survival, all metastatic prostate cancer

| SEER measure | Quoted value |
| --- | --- |
| Distant-stage five-year relative survival | “40.1%” |

Source: [National Cancer Institute SEER Cancer Stat Facts](https://seer.cancer.gov/statfacts/html/prost.html)

<a id="topic-2.2.1.3-6"></a>

###### Overall survival in metastatic castration-resistant prostate cancer, U.S. Flatiron cohort 2016 to 2023

> “Overall median OS was 24.6 months and trended lower for patients who received prior ARPi only or both prior ARPi and taxane.”

Source: [Swami et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42235146/)

<a id="topic-2.2.1.3-7"></a>

###### Overall survival in metastatic castration-resistant prostate cancer, Medicare fee-for-service cohort 2014 to 2019

> “Overall mortality in the cohort was 54%. Median survival from mCRPC diagnosis was 25.6 months (95% confidence interval [CI] 25.0–26.2 months) (Fig. 3). Median survival from treatment initiation was 23.4 months (95% CI: 22.8–24.1 months)”

Source: [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/)

<a id="topic-2.2.1.3-8"></a>

###### Overall survival in metastatic castration-resistant prostate cancer after metastatic hormone-sensitive disease, U.S. ConcertAI cohort 2020 to 2023

> “Median real-world overall survival was 27.2 months from mCRPC diagnosis and 20.8 months from 1L therapy.”
> “Back-to-back ARPI use from mHSPC to mCRPC is common in current clinical practice and survival remains <3 years.”

Source: [Raval et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40670254/)

<a id="topic-2.2.1.3-9"></a>

###### Real-world overall survival across observational studies

> “Median RW OS was ≤34 mo from either mCRPC diagnosis or initiation of first-line mCRPC treatment in most studies.”

Source: [Raval et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41266184/)

<a id="topic-2.2.1.3-10"></a>

###### Overall survival after an androgen receptor pathway inhibitor and a taxane, standard-of-care arm of a phase 3 trial

> “The median overall survival among all 831 patients who had undergone randomization was 15.3 months in the 177Lu-PSMA-617 group, as compared with 11.3 months in the control group (hazard ratio for death, 0.62; 95% CI, 0.52 to 0.74; P<0.001 [significance level, 0.05])”

Source: [Sartor et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8446332/)

<a id="topic-2.2.1.3-11"></a>

###### Overall survival by site of metastasis, docetaxel-treated trial participants

> “Men with liver metastases had the worst median OS (13.5 months). Although men with lung metastases had better median OS (19.4 months) compared with men with liver metastases, they had significantly worse median survival duration than men with nonvisceral bone metastases (21.3 months). Men with LN-only disease had a median OS of 31.6 months.”

Source: [Halabi et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872320/)

<a id="topic-2.2.1.3-12"></a>

###### Survival with castration-resistant prostate cancer before current therapies

> “The median survival of patients with CRPC was reported in five studies, with values varying from 9 to 30 months.”

Source: [Kirby et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21995694/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Androgen receptor signaling as the driver of castration resistance

> “Over the past ten years, preclinical studies implicating sustained androgen receptor (AR) signaling as the primary driver of castration resistant prostate cancer (CRPC) led to the development of novel agents targeting the AR pathway that are now in widespread clinical use.”
> “In this review, we highlight emerging mechanisms of acquired resistance to these contemporary therapies, which fall into the three broad categories of restored AR signaling, AR bypass signaling and complete AR independence.”

Source: [Watson et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4771416/)

<a id="topic-2.2.1.4-2"></a>

###### Androgen receptor pathway alterations in metastatic biopsies

> “In aggregate 107/150 (71.3%) of cases harbored AR pathway aberrations, the majority of which were direct alterations affecting AR through amplification and mutation (Fig. 4A).”
> “The high frequency of AR pathway alterations in this cohort strongly implies that the vast majority of mCRPC affected individuals remain dependent on AR signaling for viability.”

Source: [Robinson et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4484602/)

<a id="topic-2.2.1.4-3"></a>

###### DNA repair gene alterations in metastatic biopsies

> “We therefore expanded the focus to other DNA repair/recombination genes and identified alterations in at least 34/150 (22.7%) of cases.”

Source: [Robinson et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4484602/)

<a id="topic-2.2.1.4-4"></a>

###### Primary and acquired resistance to androgen receptor pathway inhibitors

> “Although enzalutamide and abiraterone represent breakthroughs in the treatment of metastatic castration-resistant prostate cancer, approximately 20 to 40% of patients have no response to these agents with respect to prostate-specific antigen (PSA) levels (i.e., they have primary resistance).”
> “Among patients who initially have a response to enzalutamide or abiraterone, virtually all eventually acquire secondary resistance.”

Source: [Antonarakis et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4201502/)

<a id="topic-2.2.1.4-5"></a>

###### Androgen receptor splice variant 7 and cross-resistance to enzalutamide and abiraterone

> “The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding domain, which is the target of enzalutamide and abiraterone, but remains constitutively active as a transcription factor.”
> “Among men receiving enzalutamide, AR-V7–positive patients had lower PSA response rates than AR-V7–negative patients (0% vs. 53%, P = 0.004)”
> “Similarly, among men receiving abiraterone, AR-V7–positive patients had lower PSA response rates than AR-V7–negative patients (0% vs. 68%, P = 0.004)”

Source: [Antonarakis et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4201502/)

<a id="topic-2.2.1.4-6"></a>

###### Androgen receptor bypass through the glucocorticoid receptor

> “Recent work reveals a novel AR pathway resistance mechanism analogous to one originally described for kinase inhibitors, in which signaling downstream of the targeted kinase is restored by activation of a related kinase not targeted by the inhibitor”

Source: [Watson et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4771416/)

<a id="topic-2.2.1.4-7"></a>

###### Lineage plasticity and neuroendocrine differentiation after androgen receptor pathway inhibitors

> “With the growing clinical use of abiraterone and enzalutamide, it is increasingly appreciated that some men can relapse with clinically aggressive variants of PCa with reduced or absent AR expression.”

Source: [Watson et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4771416/)

> “An increasingly recognized resistance mechanism to androgen receptor (AR)-directed therapy in prostate cancer involves epithelial plasticity, wherein tumor cells demonstrate low to absent AR expression and often neuroendocrine features.”

Source: [Beltran et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4777652/)

<a id="topic-2.2.1.4-8"></a>

###### EZH2 expression in castration-resistant neuroendocrine prostate cancer

> “was 2 fold higher in CRPC-NE compared to CRPC-Adeno (P < 10−6, Wilcoxon test); EZH2 protein was also more abundant in CRPC-NE”

Source: [Beltran et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4777652/)

<a id="topic-2.2.1.4-9"></a>

###### PRC2 and EZH2 inhibition restoring antiandrogen sensitivity in preclinical models

> “Ezh2 is the enzymatic component of the Polycomb Repressive complex 2 that methylates the lysine 27 residue of histone H3.”
> “Clinically relevant Ezh2 inhibitors restore androgen receptor expression and sensitivity to antiandrogen therapy.”

Source: [Ku et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5367887/)

<a id="topic-2.2.1.4-10"></a>

###### EZH2 as an androgen receptor coactivator in castration-resistant cells

> “Here we report that the oncogenic function of EZH2 in castration-resistant prostate cancer (CRPC) is independent of its role as a transcriptional repressor. Instead, it involves the ability of EZH2 to act as a co-activator for critical transcription factors including the androgen receptor (AR).”

Source: [Xu et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3625962/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### PSA progression criteria in clinical trials

> “After decline from baseline: record time from start of therapy to first PSA increase that is ≥ 25% and ≥ 2 ng/mL above the nadir, and which is confirmed by a second value ≥ 3 weeks later (ie, a confirmed rising trend)”

Source: [Scher et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872347/)

<a id="topic-2.2.1.5-2"></a>

###### Bone scan progression criteria in clinical trials

> “At least two new lesions on first post-treatment scan, with at least two additional lesions on the next scan (2+2 rule)”

Source: [Scher et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872347/)

<a id="topic-2.2.1.5-3"></a>

###### Soft-tissue and nodal progression criteria in clinical trials

> “PCWG3 recommends that lymph nodes that were previously normal in size (< 1.0 cm) or pathologic in size must have grown by at least 5 mm in the short axis from baseline or nadir and be ≥ 1.0 cm in the short axis to be considered to have progressed.”

Source: [Scher et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872347/)

<a id="topic-2.2.1.5-4"></a>

###### Imaging and laboratory assessment in castration-resistant disease

> “Baseline examinations should include a medical history, clinical examination, as well as baseline blood tests (PSA, total testosterone level, full blood count, renal function, baseline liver function tests, alkaline phosphatase), bone scan and CT of chest, abdomen and pelvis”
> “for monitoring disease activity in advanced CRPC, since visceral metastases may develop in men without rising PSA”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.1.5-5"></a>

###### Imaging cadence in clinical trials

> “To minimize patient exposure to ineffective treatment, and to better assess the timing of the antitumor effects of an agent for which the optimal timing is not known, an 8- to 9-week assessment interval for the first 6 months and every 12 weeks thereafter is advised.”

Source: [Scher et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872347/)

<a id="topic-2.2.1.5-6"></a>

###### PSMA PET imaging before PSMA-targeted radioligand therapy

> “Documentation of PSMA expression in metastatic sites is required prior to the initiation of RLT.”
> “The diagnostic accuracy of PSMA-ligand PET/CT for bone assessment was superior to that of bone scan”

Source: [Fendler et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10027805/)

> “The use of choline or PSMA PET/CT scans for progressing CRPC is unclear and most likely not as beneficial as for patients with BCR or hormone-naive disease.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.1.5-7"></a>

###### Germline and somatic genomic testing

> “Patients with metastatic prostate cancer should undergo both germline and somatic DNA sequencing using panel-based assays. These tests can guide the use of poly(ADP-ribose) polymerase inhibitors, which have a survival benefit in metastatic castration-resistant prostate cancer.”

Source: [Yu et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39787437/)

> “Offer mCRPC patients somatic and/or germline molecular testing, as well as testing for mismatch repair deficiencies or microsatellite instability, if not done previously.”
> “Metastatic patients should be offered somatic genomic testing for homologous repair and MMR defects early on.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

Additional sources: [NCCN (2026)](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Biochemical presentation: rising PSA before imaging or symptoms

> “A rising PSA is typically the first sign of tumor regrowth, followed later by worsening of disease by imaging and the development of clinical symptoms.”

Source: [Scher et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872347/)

<a id="topic-2.2.1.6-2"></a>

###### Skeletal symptoms: bone pain from bone metastases

> “Pain in the hips, back (spine), chest (ribs), or other areas , from cancer that has spread to the bones”

Source: [American Cancer Society signs and symptoms (2026)](https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/signs-symptoms.html)

> “Most patients with CRPC have painful bone metastases.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

> “prostate cancer may also present with symptoms of metastases, including bone pain, pathological fractures, or symptoms caused by bone marrow involvement.”

Source: [National Cancer Institute Prostate Cancer Treatment PDQ](https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq)

<a id="topic-2.2.1.6-3"></a>

###### Neurological symptoms: spinal cord compression

> “Weakness or numbness in the legs or feet , or even loss of bladder or bowel control , from cancer in the spine pressing on the spinal cord”

Source: [American Cancer Society signs and symptoms (2026)](https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/signs-symptoms.html)

<a id="topic-2.2.1.6-4"></a>

###### Urinary symptoms: obstruction from local tumor growth

> “Problems urinating , including a slow or weak urinary stream or the need to urinate more often, especially at night”

Source: [American Cancer Society signs and symptoms (2026)](https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/signs-symptoms.html)

> “Nevertheless, local growth of the tumor may produce symptoms of urinary obstruction such as:”

Source: [National Cancer Institute Prostate Cancer Treatment PDQ](https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq)

<a id="topic-2.2.1.6-5"></a>

###### Constitutional symptoms: weight loss and fatigue

> “Weight loss”
> “Feeling very tired”

Source: [American Cancer Society signs and symptoms (2026)](https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/signs-symptoms.html)

<a id="topic-2.2.1.6-6"></a>

###### Pattern of metastatic spread at diagnosis of castration resistance

> “Bone metastases were present in ≥80% and visceral metastases in ≤28% of cases at mCRPC diagnosis.”

Source: [Raval et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41266184/)

> “Most patients had bone with or without LN metastases (72.8%), followed by visceral disease (20.8%) and LN-only disease (6.4%).”

Source: [Halabi et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872320/)

<a id="topic-2.2.1.6-7"></a>

###### Sites of metastasis, all metastatic prostate cancer

> “The most common metastatic sites were bone (84%), distant lymph nodes (10.6%), liver (10.2%), and thorax (9.1%).”

Source: [Gandaglia et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24132735/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Skeletal complications of bone metastases in castration-resistant disease

> “Common complications due to bone metastases include vertebral collapse or deformity, pathological fractures and spinal cord compression.”
> “Impending spinal cord compression is an emergency.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.1.7-2"></a>

###### Skeletal-related events and symptomatic skeletal events as defined for trials

> “PCWG2 did not consider skeletal-related events (SREs), which include asymptomatic nonclinical fractures ascertained by serial imaging, clinical pathologic fractures, spinal cord compression, and surgery or radiation therapy to bone.”
> “PCWG3 advises reporting SSEs that include only symptomatic events of clear clinical significance, in contrast to SREs, which also include asymptomatic fractures.”

Source: [Scher et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872347/)

<a id="topic-2.2.1.7-3"></a>

###### Skeletal-related events without bone-targeted therapy, placebo arm of a randomized trial

> “A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021)”
> “Median time to first skeletal-related event was 321 days for patients who received placebo”

Source: [Saad et al. (2002)](https://pubmed.ncbi.nlm.nih.gov/12359855/)

<a id="topic-2.2.1.7-4"></a>

###### Skeletal-related events by type during bone-targeted therapy in metastatic castration-resistant prostate cancer

| First on-study skeletal-related event | Zoledronic acid (n=951) | Denosumab (n=950) |
| --- | --- | --- |
| Total confirmed events | “386 (41%)” | “341 (36%)” |
| Radiation to bone | “203 (21%)” | “177 (19%)” |
| Pathological fracture | “143 (15%)” | “137 (14%)” |
| Spinal cord compression | “36 (4%)” | “26 (3%)” |
| Surgery to bone | “4 (<1%)” | “1 (<1%)” |

Source: [Fizazi et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3090685/)

<a id="topic-2.2.1.7-5"></a>

###### Cumulative incidence of skeletal-related events after diagnosis of bone metastasis, U.S. health systems

> “SREs were present at diagnosis of bone metastasis in 22.4, 22.4, and 10.0 % of BC, LC, and PC patients, respectively.”
> “In BC, cumulative incidence of SREs during follow-up was 38.7 % at 6 months, 45.4 % at 12 months, and 54.2 % at 24 months; in LC, it was 41.0, 45.4, and 47.7 %; and in PC, it was 21.5, 30.4, and 41.9 %.”

Source: [Oster et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23884473/)

<a id="topic-2.2.1.7-6"></a>

###### Skeletal-related events and survival, SEER-Medicare men with prostate cancer metastatic to bone

> “Among 3,297 men with prostate cancer metastatic to bone, 40% experienced ≥1 SRE (median follow-up, 19 months). Compared with men who remained SRE-free, men with ≥1 SRE had a twofold higher risk for death (HR, 2.29; 95% CI, 2.09–2.51). Pathological fracture was associated with the highest risk for death (HR, 2.77; 95% CI, 2.38–3.23).”

Source: [McDougall et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4786354/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Patient-reported impact on daily life: multinational survey

> “A total of 221 patients with mCRPC and 159 caregivers from USA, France, Germany, Canada, Spain, China, and Brazil were surveyed. mCRPC impacts mood, emotional and mental health (50–77%), sleep (48–68%), career goals (48–80%), and social activities (46–65%).”
> “Patients face high treatment and pill burden (7–12 pills/day) and prefer simpler treatment regimens.”
> “For many patients (52% to 73%), ≥9 hours per week were devoted to mCRPC care.”
> “One in three patients experiences fatigue, which is persistent and happens during day-to-day activities (Figure 2(b)).”

Source: [Jain et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12218467/)

<a id="topic-2.2.1.8.1-2"></a>

###### Real-world deterioration of health-related quality of life and pain

> “In total, 151 included patients answered 873 questionnaires.”
> “At inclusion, generic HRQoL was high with a mean EQ visual analog score of 73.2 out of 100. The lowest scores were reported on role and physical functioning (mean scores of 69 and 76 of 100, respectively), and fatigue, pain, and insomnia were the most impaired domains. These domains deteriorated in > 50% of patients.”
> “mCRPC has a negative impact on HRQoL with deterioration in all domains over time, especially role and physical functioning.”

Source: [Kuppen et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31883940/)

<a id="topic-2.2.1.8.1-3"></a>

###### Health state utility values by disease state

> “Data were collected from a total sample of 163 men with metastatic CRPC. Utility values elicited by the EQ-5D-5L ranged from 0.830 for the asymptomatic/mildly symptomatic before chemotherapy disease state (95% confidence interval [CI] 0.795-0.865) to 0.625 for the symptomatic before chemotherapy disease state (95% CI 0.577-0.673).”
> “EORTC-8D utilities ranged from 0.856 (95% CI 0.831-0.882) to 0.697 (95% CI 0.664-0.731) for the same disease/treatment states.”

Source: [Lloyd et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26686802/)

<a id="topic-2.2.1.8.1-4"></a>

###### Pooled health state utility values by line of therapy: meta-analysis

> “In primary studies, baseline EQ-5D index utility values ranged from 0.7 to 0.9 in 1L and 0.63 to 0.7 in 2L+.”
> “The pooled mean baseline EQ-5D index utility value was estimated as 0.79 (95% CI, 0.70–0.84) and 0.69 (95% CI, 0.67–0.71) for 1L (n = 7 studies) and 2L + (n = 4 studies), respectively.”
> “The pooled mean baseline EQ VAS score was estimated as 74.63 (95% CI, 70.97–78.29) and 65.82 (95% CI, 64.53–67.11) in 1L and 2L+, respectively.”

Source: [Castro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12311294/)

<a id="topic-2.2.1.8.1-5"></a>

###### Time to worsening after progression on one androgen receptor pathway inhibitor

> “Eligible patients had metastatic castration-resistant prostate cancer, were candidates for ARPI change after one progression on a previous ARPI”
> “In the [177Lu]Lu-PSMA-617 versus ARPI change groups, median time to worsening in FACT-P total score was 7·46 months (95% CI 6·08-8·54) versus 4·27 months (3·45-4·50; hazard ratio [HR] 0·61 [95% CI 0·50-0·75]), in EQ-5D-5L utility score was 6·28 months (4·70-7·89) versus 3·88 months (3·25-4·44; 0·67 [0·54-0·82]), and in BPI-SF pain intensity was 5·03 months (4·40-6·80) versus 3·65 months (3·09-4·37; 0·72 [0·59-0·88]).”
> “median time to first symptomatic skeletal event was not reached (95% CI not estimable [NE]-NE) in the [177Lu]Lu-PSMA-617 group versus 17·97 months (14·26-NE) in the ARPI change group (HR 0·41 [0·26-0·63]).”

Source: [Fizazi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40441170/)

<a id="topic-2.2.1.8.1-6"></a>

###### Pain progression with a second androgen receptor pathway inhibitor after docetaxel

> “Pain response was observed in 51 (46%) of 111 patients with cabazitaxel and 21 (19%) of 109 patients with abiraterone or enzalutamide (p<0·0001). Median time to pain progression was not estimable (NE; 95% CI NE-NE) with cabazitaxel and 8·5 months (4·9-NE) with abiraterone or enzalutamide (hazard ratio [HR] 0·55, 95% CI 0·32-0·97; log-rank p=0·035).”
> “Median time to FACT-P total score deterioration was 14·8 months (95% CI 6·3-NE) with cabazitaxel and 8·9 months (6·3-NE) with abiraterone or enzalutamide (HR 0·72, 95% CI 0·44-1·20; log-rank p=0·21).”

Source: [Fizazi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32926841/)

<a id="topic-2.2.1.8.1-7"></a>

###### Pain, skeletal events, and health-related quality of life after taxane and androgen receptor pathway inhibitor

> “Pain in patients with mCRPC can be attributed largely to bone metastases, lumbosacral invasion, and nerve root compression, and is associated with shortened OS.”
> “Time to worsening was delayed in the 177Lu-PSMA-617 plus SoC group (n = 385) versus SoC alone (n = 196) for FACT-P total score (HR, 0·46; 95% CI: 0·35, 0·61) and subdomains, BPI-SF pain intensity score (HR, 0·45; 95% CI: 0·33, 0·60) and EQ-5D-5L utility score (HR, 0·49; 95% CI: 0·40, 0·62).”
> “SSEs occurred in 60/385 patients (16%) in the 177Lu-PSMA-617 group and 34/196 patients (17%) in the control group (table 2). The predominant types of SSE were radiation to relieve bone pain, followed by spinal cord compression (table 2).”

Source: [Fizazi et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10641914/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Cost increase at progression to castration resistance

> “Among 296 patients with mCSPC progressing to mCRPC (median age 69.0 years, 60.5% White, 15.9% Black)”
> “The mean number of days with PC-related outpatient visits increased from 1.57 to 2.16 PPPM in the mCSPC and mCRPC disease states (P < 0.001). From the mCSPC to mCRPC disease states, mean all-cause total health care costs PPPM increased from $4,424 (medical costs: $2,846) to $9,717 (medical costs: $4,654), and mean PC-related total health care costs PPPM increased from $2,859 (medical costs: $1,626) to $8,012 (medical costs: $3,285; all P < 0.001).”

Source: [Kaye et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11217864/)

<a id="topic-2.2.1.8.2-2"></a>

###### Costs during first-line therapy: commercial, Medicare Advantage, and Medicaid claims

> “Among 459 patients with mCRPC (mean age 70 years, 57% White, 16% Black, 45% commercially-insured, 43% Medicare Advantage-insured, and 12% Medicaid-insured), average baseline all-cause total costs (PPPM) were $4,576 ($4,166 pre-mCRPC progression, $8,278 post-mCRPC progression).”
> “During an average 1 L duration of 8.5 months, mean total costs were $13,746 (all-cause) and $12,061 (PC-related) PPPM.”
> “PC-related medical costs PPPM increased from $1,504 during baseline to $5,585 following 1 L mCRPC therapy initiation.”

Source: [Kaye et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/38204397/)

<a id="topic-2.2.1.8.2-3"></a>

###### Medicare fee-for-service resource use by line of therapy

> “A total of 14,780 men with mCRPC were identified. After mCRPC diagnosis, 11,528 men initiated 1L mCRPC therapy, 6275 initiated 2L, and 2945 initiated 3L.”
> “All-cause medical HRU (days PPPY) increased after mCRPC diagnosis and from 1L through 3L treatment, particularly for outpatient care (pre-diagnosis, 10.4; 1L, 16.2; 2L, 18.9; 3L, 22.0) and physician/other visits (pre-diagnosis, 30.1; 1L, 46.5; 2L, 50.2; 3L, 56.9).”
> “After mCRPC diagnosis, 11,528 (78%) patients received life-prolonging therapy and 3252 (22%) patients did not.”

Source: [Freedland et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10500004/)

<a id="topic-2.2.1.8.2-4"></a>

###### Medicare fee-for-service costs by line of therapy

| Period | All-cause medical and pharmacy, mean per patient per year (2019 USD) | Prostate cancer-related medical, mean per patient per year (2019 USD) |
| --- | --- | --- |
| Year before mCRPC diagnosis | “27,468” | “11,411” |
| After mCRPC diagnosis, all patients | “124,379” | “52,609” |
| After diagnosis, no life-prolonging therapy | “102,380” | “51,076” |
| First line | “148,325” | “69,063” |
| Second line | “160,118” | “73,467” |
| Third line | “165,186” | “95,240” |

Source: [Freedland et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10500004/)

<a id="topic-2.2.1.8.2-5"></a>

###### Older Medicare beneficiaries: resource use and costs per patient-year

> “A total of 4758 patients met the eligibility criteria and received 1L treatment.”
> “On average, patients had 1.2 inpatient admissions, 1.1 emergency room visits, and 27.6 outpatient visits per year during follow-up. The mean total all-cause and PC-related costs during the follow-up period were $111,060 and $99,540 per-patient-per-year, respectively.”

Source: [Swami et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37248148/)

<a id="topic-2.2.1.8.2-6"></a>

###### Second androgen receptor pathway inhibitor or taxane after a first: resource use in Medicare

> “Patients with mCRPC who previously received one androgen receptor pathway inhibitor (ARPI) followed by either a second ARPI (ARPI cohort) or a taxane (taxane cohort) were included.”
> “Of 923 patients, 714 were in the ARPI cohort and 209 in the taxane cohort.”
> “Median OS was ≈1 year in both cohorts. SAEs were more frequent in the taxane cohort (66.0% vs 42.2%; p < 0.001). The taxane cohort had more ER, outpatient, and pharmacy visits (p < 0.0001), while the ARPI cohort had more hospitalizations (p < 0.0001).”

Source: [McKay et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42836510/)

<a id="topic-2.2.1.8.2-7"></a>

###### Taxane adverse event costs after first-line androgen receptor pathway inhibitor

> “Overall, 2L ARPI (n = 473) vs. taxane (n = 214) was associated with longer median OS (15.4 vs. 13.6 months).”
> “Patients receiving > 8 vs. ≤ 8 taxane cycles were also more likely to experience an AE (95% vs. 88%) but had lower mean AE-related total healthcare costs per patient per month ($3,429 vs. $6,334).”
> “Overall, only 22% of patients in the Flatiron cohort and 13% in the PharMetrics cohort received > 8 cycles of taxanes, while 78% and 87%, respectively, were early discontinuers.”

Source: [Shore et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13401553/)

<a id="topic-2.2.1.8.2-8"></a>

###### Insurer drug payments by first-line agent: employer-sponsored insurance

> “This retrospective cohort study included 4,298 patients with prostate cancer who initiated therapy with one of six drugs approved for first-line treatment of mCRPC between July 1, 2013, and June 30, 2019.”
> “Over the 6 months after the index prescription, mean unadjusted gross drug payments were highest for patients receiving sipuleucel-T ($115,525 USD) and lowest for patients using docetaxel ($12,804 USD).”

Source: [Kaye et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10113111/)

<a id="topic-2.2.1.8.2-9"></a>

###### Skeletal-related events: attributable Medicare cost

> “HCRU and costs (in 2013 U.S. dollars) were evaluated in a propensity score-matched cohort by using Poisson regression and Kaplan-Meier sample average estimators, respectively.”
> “Among 3,297 men with prostate cancer metastatic to bone, 40% experienced ≥1 SRE (median follow-up, 19 months).”
> “Among men with ≥1 SRE, emergency department visits were twice as frequent (95% CI, 1.77–2.28) and hospitalizations were nearly four times as frequent (95% CI, 3.20–4.40). The attributable cost of ≥1 SRE was $21,191 (≥1 SRE: $72,454 [95% CI, $67,362–$76,958]; SRE-free: $51,263 [95% CI, $45,439–$56,100]).”

Source: [McDougall et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4786354/)

Additional sources: [Hagiwara et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23146970/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Caregiver time, finances, and employment

> “Caregivers often spouses or partners, provide practical, financial, and emotional support, averaging 11 hours/week of providing care.”
> “For the majority of caregivers (58% to 60%), providing care affects their finances (60%), sleep (60%), energy level (59%), mood/mental health (58%), and overall day-to-day life (58%). More than half of caregivers (53%) report an impact on their ability to work.”
> “Among the 79% of caregivers who worked outside the home before their patient’s mCRPC diagnosis, 40% reduced their working hours, 13% stopped working completely, 3% retired as planned, and 43% made other changes; only 15% continued working normally post-diagnosis (Supplementary Table S1). Among those who reduced work hours, 64% reduced their hours by half or more.”

Source: [Jain et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12218467/)

<a id="topic-2.2.1.8.3-2"></a>

###### Prevalence of high financial toxicity and coping behaviors

> “Overall, 281 patients met inclusion criteria of which 79 reported high financial toxicity.”
> “Patients with high financial toxicity were more likely to decrease spending on basic goods (35% vs 2.5%, P < .001) and leisure activities (59% vs 15%, P > .001), as well as use savings (62% vs 17%, P < .001) to pay for their treatment.”

Source: [Joyce et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37416955/)

<a id="topic-2.2.1.8.3-3"></a>

###### Indirect costs and the role of informal caregivers

> “Qualitative descriptions were congruent with quantitative items assessing indirect costs of treatment, with many patients describing alterations to work, early retirement, and caregiver lifestyle changes (Quotes 1.2.2, 1.2.3, 1.2.5). Additional indirect costs not evaluated by the quantitative assessment included the opportunity cost of time spent navigating insurance coverage, as well as costs of travel to treatment sites, including gas, commute time, hotel expenses, and even relocating to be closer to care (Quotes 1.2.2, 1.2.4, 1.2.7).”
> “In addition, how treatment costs impacted the lives of patients’ loved ones was a strong contributor to the degree of financial stress that they experienced (Quotes 3.3.3, 3.3.4).”

Source: [Joyce et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11192241/)

<a id="topic-2.2.1.8.3-4"></a>

###### Out-of-pocket payments for oral androgen receptor pathway inhibitors under Medicare Part D

> “There were 4,153 patients who filled abiraterone or enzalutamide through Medicare Part D in 228 hospital-referral regions. Mean adherence was 75%. Median monthly out-of-pocket payment for abiraterone and enzalutamide was $706 (range $0 to $3,505).”

Source: [Caram et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7959094/)

<a id="topic-2.2.1.8.3-5"></a>

###### Out-of-pocket payments by first-line agent: employer-sponsored insurance

> “OOP payments were lower than gross drug payments; mean 6-month OOP payments were highest for cabazitaxel ($1,044 USD) and lowest for docetaxel ($296 USD). There was a wide distribution of OOP payments within drug types.”

Source: [Kaye et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10113111/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Genetic testing rates before PARP inhibitor approval: United States oncology records

> “Of 5213 mCRPC patients, 674 (13%) had a documented genetic test. The number of tested patients increased from 1 in 2013 to 313 in 2018 (out of 3161 and 3010 clinically active patients, respectively). Receiving care in an academic oncology center (versus a community-based center) strongly predicted genetic testing (hazard ratio = 2.41).”

Source: [Shore et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33906368/)

<a id="topic-2.2.1.8.4-2"></a>

###### Biomarker testing rates in metastatic prostate cancer: United States community oncology network

> “For these metastatic subgroups, biomarker testing rates were 80% (NSCLC), 34% (prostate), and 42% (bladder). Median time from disease diagnosis to first test order was 10 days (NSCLC), 98 days (prostate), and 23 days (bladder), with differences observed across racial and ethnic groups.”
> “Among tested patients, actionable mutations were identified in 29% (NSCLC), 25% (prostate), and 14% (bladder) of patients, and targeted therapy was received by 54%, 15%, and 38% of these patients, respectively.”

Source: [Mahmud et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13348720/)

<a id="topic-2.2.1.8.4-3"></a>

###### Genomic testing rates and BRCA yield: Dutch registry

> “Among 1996 mCRPC patients, genomic analysis (somatic and/or germline) was performed in 23.4% (range 3.8–63.2% across hospitals), identifying BRCAm in 11.3% of patients.”

Source: [Bosch et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13287194/)

<a id="topic-2.2.1.8.4-4"></a>

###### Tissue availability for somatic genomic testing

> “A total of 150 pts were enrolled. All had germline and initial ctDNA testing. Results from tissue testing were available in 72 pts.”
> “Sequencing results from tissue were available in only half of pts, highlighting the challenges of obtaining tumor tissue for genomic testing.”

Source: [Shevrin et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42161163/)

<a id="topic-2.2.1.8.4-5"></a>

###### Genomic test-directed olaparib: United States payer model

> “Olaparib yielded an additional 0.063 and 0.068 of quality-adjusted life year (QALY) with the augmented cost of $7,382 and saved the cost of $ 1,980 compared to standard care in scenario A and B, respectively, which yielded an ICER of $116,903/QALY and a cost-saving option.”
> “Included the NGS cost ($5,800).”

Source: [Su et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7870786/)

<a id="topic-2.2.1.8.4-6"></a>

###### Germline BRCA testing-guided olaparib: Australian payer model

> “Compared to standard care, BRCA testing-guided olaparib treatment was associated with an incremental cost of AU$7,841 and a gain of 0.06 quality-adjusted life-years (QALYs). The incremental cost-effectiveness ratio (ICER) was AU$143,613 per QALY.”

Source: [Teppala et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11570197/)

<a id="topic-2.2.1.8.4-7"></a>

###### Germline BRCA testing with cascade testing of relatives: Australian payer model

> “Compared with no testing, BRCA testing in mPCa was associated with an incremental cost of AU$3731 and a gain of 0.014 quality-adjusted life-years (QALYs), resulting in an incremental cost-effectiveness ratio of AU$265 942/QALY. Extending testing to FDRs of variant-positive patients resulted in an incremental cost-effectiveness ratio of AU$16 392/QALY.”

Source: [Teppala et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38977196/)

<a id="topic-2.2.1.8.4-8"></a>

###### Cost per PSMA PET scan used in a United States model

| Imaging input | Cost (2021 USD) |
| --- | --- |
| Piflufolastat F 18 PET | “6274.17” |
| Gallium 68 PSMA-11 PET | “6036.17” |
| Fluciclovine F 18 PET | “6336.17” |
| Computed tomography | “241.90” |

Source: [Yee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10811023/)

<a id="topic-2.2.1.8.4-9"></a>

###### PSMA PET cost-effectiveness in biochemical recurrence: United States model

> “PSMA-PET had mean increments of $99 000 (95% UI, $55 000-153,000) in costs and 0.58 QALYs (95% UI, 0.35-0.82 QALYs) compared with CTBS, leading to an ICER of $172 000 per QALY, which exceeded the assumed $150 000/QALY willingness-to-pay threshold.”
> “This study found that PSMA-PET may be associated with improved disease detection but may not be cost-effective due to high treatment costs offsetting moderate improvements in QALYs.”

Source: [Kunst et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12552925/)

<a id="topic-2.2.1.8.4-10"></a>

###### PSMA PET cost-effectiveness: systematic review

> “A total of seven studies were examined, representing both private and public healthcare systems. Overall, these studies demonstrate high methodological and reporting quality. When compared to existing imaging technologies or standard care practices, PSMA-PET/CT or MRI is cost-effective within country-specific willingness-to-pay thresholds.”

Source: [Sanyal and Rendon (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13033869/)

Additional sources: [de Feria Cardet et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33341285/); [George et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42431822/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Androgen Deprivation Therapy

<a id="topic-2.2.2.1.1-1"></a>

###### Continued castration in metastatic castration-resistant disease: guideline statements

> “However, in the absence of prospective data, the modest potential benefits of continuing castration outweigh the risk of treatment.”
> “In addition, all subsequent treatments have been studied in men with ongoing androgen suppression, therefore, it should be continued in these patients.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.1-2"></a>

###### Continued castration in hormone-refractory disease: treatment summary

> “Patients treated with either luteinizing-hormone agonists or estrogens as primary therapy are generally maintained with castrate levels of testosterone.”
> “One study from the Eastern Cooperative Oncology Group (ECOG) showed that a superior survival resulted when patients were maintained on primary androgen deprivation”
> “another study from SWOG (formerly the Southwest Oncology Group) did not show an advantage to continued androgen blockade.”

Source: [National Cancer Institute Prostate Cancer Treatment PDQ](https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq)

<a id="topic-2.2.2.1.1-3"></a>

###### Concurrent gonadotropin-releasing hormone analog or orchiectomy in androgen receptor pathway inhibitor labeling

> “Patients receiving XTANDI for castration-resistant prostate cancer, or metastatic castration-sensitive prostate cancer should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.”

Source: [Xtandi prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/203415s026lbl.pdf)

> “Patients receiving ZYTIGA should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.”

Source: [Zytiga prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202379s035lbl.pdf)

> “Patients receiving NUBEQA should also receive a gonadotropin-releasing hormone (GnRH) agonist or antagonist concurrently or have had a bilateral orchiectomy.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.2.2.1.1-4"></a>

###### Continued androgen deprivation in post-inhibitor trials

> “Patients were required to be surgically or medically castrated with a castrate level of serum testosterone at study entry.”
> “If patients were being treated with androgen deprivation therapy (ADT), therapy was continued throughout the study.”

Source: [Rubraca prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf)

> “All patients maintained castration therapy during the trial.”

Source: [de Bono et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28844372/)

Additional sources: [AUA (2026)](https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer); [Fizazi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41679466/); [NCCN (2026)](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Androgen Receptor Pathway Inhibitors

<a id="topic-2.2.2.1.2-1"></a>

###### Enzalutamide: FDA-approved indications

> “XTANDI is an androgen receptor inhibitor indicated for the treatment of patients with:”
> “castration-resistant prostate cancer (CRPC)”
> “metastatic castration-sensitive prostate cancer (mCSPC)”

Source: [Xtandi prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/203415s026lbl.pdf)

<a id="topic-2.2.2.1.2-2"></a>

###### Abiraterone acetate: FDA-approved indications

> “ZYTIGA is indicated in combination with prednisone for the treatment of patients with”
> “Metastatic castration-resistant prostate cancer (CRPC)”
> “Metastatic high-risk castration-sensitive prostate cancer (CSPC)”

Source: [Zytiga prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202379s035lbl.pdf)

<a id="topic-2.2.2.1.2-3"></a>

###### Apalutamide: FDA-approved indications

> “ERLEADA is indicated for the treatment of patients with”
> “Metastatic castration-sensitive prostate cancer (mCSPC)”
> “Non-metastatic castration-resistant prostate cancer (nmCRPC)”

Source: [Erleada prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/210951s024lbl.pdf)

<a id="topic-2.2.2.1.2-4"></a>

###### Darolutamide: FDA-approved indications

> “NUBEQA is indicated for the treatment of adult patients with:”
> “non-metastatic castration resistant prostate cancer (nmCRPC)”
> “metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.2.2.1.2-5"></a>

###### Guideline statements on sequencing androgen receptor pathway inhibitors

> “In general, sequencing of ARPIs like abiraterone and enzalutamide is not recommended particularly if the time of response to ADT and to the first ARPI was short (≤ six to twelve months) and high-risk features of rapid progression are present”
> “This cross resistance with abiraterone should also be extrapolated to apalutamide and darolutamide.”
> “Also, the sequential use of the lutamides (apalutamide, darolutamide, enzalutamide) is not recommended as the mode of action is very similar.”
> “Avoid sequencing of androgen receptor-targeted agents.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.2-6"></a>

###### Absence of comparative sequencing trials

> “Because there are no head-to-head comparisons, there are no trials to help decide which of these agents should be used first or in what sequence they should be used.”

Source: [National Cancer Institute Prostate Cancer Treatment PDQ](https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq)

<a id="topic-2.2.2.1.2-7"></a>

###### Randomized crossover trial of abiraterone and enzalutamide sequences

> “Primary endpoints were time to second PSA progression and PSA response (≥30% decline from baseline) on second-line therapy, analysed by intention-to-treat in all randomly assigned patients and in patients who crossed over, respectively.”
> “PSA responses to second-line therapy were seen in 26 (36%) of 73 patients for enzalutamide and three (4%) of 75 for abiraterone (χ2 p<0·0001).”
> “Enzalutamide showed activity as a second-line novel androgen receptor pathway inhibitor, whereas abiraterone acetate did not, leading to a longer time to second PSA progression for the sequence of abiraterone followed by enzalutamide than with the opposite treatment sequence.”

Source: [Khalaf et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31727538/)

<a id="topic-2.2.2.1.2-8"></a>

###### Single-arm study of enzalutamide after abiraterone

> “Multicentre, single-arm, open-label study, enrolled patients with progressing mCRPC after ≥24 wk of abiraterone acetate plus prednisone treatment.”
> “Median radiographic progression-free survival was 8.1 mo (95% confidence interval: 6.1-8.3); median overall survival had not been reached.”
> “Unconfirmed PSA response rate was 27% (48 of 181).”
> “Although cross-resistance between the two agents was observed in a majority of patients, some still benefited from enzalutamide treatment.”

Source: [de Bono et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28844372/)

<a id="topic-2.2.2.1.2-9"></a>

###### Adding enzalutamide to abiraterone at PSA progression on enzalutamide: PLATO

> “Median progression-free survival was 5.7 months in the combination group and 5.6 months in the control group (hazard ratio, 0.83; 95% CI, 0.61 to 1.12; P = .22).”
> “PLATO also reported limited benefit with abiraterone after enzalutamide.”
> “Overall, results from PLATO suggest that enzalutamide should not be continued in combination with abiraterone after PSA progression during enzalutamide monotherapy.”

Source: [Attard et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6118405/)

<a id="topic-2.2.2.1.2-10"></a>

###### Second inhibitor after docetaxel and one inhibitor: CARD control arm

> “The median imaging-based progression-free survival was 8.0 months with cabazitaxel and 3.7 months with the androgen-signaling-targeted inhibitor.”
> “The median overall survival was 13.6 months with cabazitaxel and 11.0 months with the androgen-signaling-targeted inhibitor (hazard ratio for death, 0.64; 95% CI, 0.46 to 0.89; P = 0.008).”
> “a prostate-specific antigen response occurred in 35.7% and 13.5% of the patients, respectively (P<0.001)”

Source: [de Wit et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31566937/)

<a id="topic-2.2.2.1.2-11"></a>

###### Change of inhibitor in taxane-naive disease: PSMAfore control arm

> “Eligible patients were adults with PSMA-positive mCRPC who were candidates for a change of ARPI following one instance of disease progression on abiraterone, enzalutamide, darolutamide, or apalutamide as their most recent anticancer therapy.”
> “At third data cut-off after 334 rPFS events, the updated hazard ratio for radiographic progression or death with 177 Lu-PSMA-617 vs ARPI change was 0·49 (95% CI, 0·39–0·61); the median rPFS was 11·60 months (95% CI, 9·30–14·19) vs 5·59 months (4·21–5·95)”
> “At third data cut-off, the proportion of patients with confirmed prostate-specific antigen (PSA) decline of at least 50% from baseline was higher with 177 Lu-PSMA-617 vs ARPI change (51% [95% CI, 43·8–57·5] vs 17% [12·6–22·9])”
> “In the ARPI change group, the median duration of exposure was 6·52 months (IQR, 7·77); 100 patients received abiraterone and 132 patients received enzalutamide.”

Source: [Morris et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12121614/)

<a id="topic-2.2.2.1.2-12"></a>

###### Second inhibitor as control in BRCA-altered disease: TRITON3

> “the median duration was also longer with rucaparib than with abiraterone acetate or enzalutamide (11.2 months vs. 4.5 months; hazard ratio, 0.38; 95% CI, 0.25 to 0.58)”

Source: [Fizazi et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10064172/)

Additional sources: [AUA (2026)](https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer); [Fizazi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41679466/); [NCCN (2026)](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Taxane and Platinum Chemotherapy

<a id="topic-2.2.2.1.3-1"></a>

###### Docetaxel: FDA-approved indication and TAX327 overall survival

> “TAXOTERE in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.”
> “For metastatic castration-resistant prostate cancer, the recommended dose of TAXOTERE is 75 mg/m2 every 3 weeks as a 1 hour intravenous infusion.”

Source: [Taxotere prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020449s086lbl.pdf)

| Outcome | Docetaxel plus prednisone every 3 weeks | Mitoxantrone plus prednisone every 3 weeks |
| --- | --- | --- |
| Median survival, months (95% CI) | “18.9 (17.0-21.2)” | “16.5 (14.4-18.6)” |
| Hazard ratio (95% CI) | “0.761 (0.619-0.936)” | Not applicable |

Source: [Taxotere prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020449s086lbl.pdf)

<a id="topic-2.2.2.1.3-2"></a>

###### Docetaxel: TAX327 publication

> “As compared with the men in the mitoxantrone group, men in the group given docetaxel every three weeks had a hazard ratio for death of 0.76 (95 percent confidence interval, 0.62 to 0.94; P=0.009 by the stratified log-rank test)”
> “Among these three groups, 32 percent, 45 percent, and 48 percent of men, respectively, had at least a 50 percent decrease in the serum PSA level (P<0.001 for both comparisons with mitoxantrone)”

Source: [Tannock et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15470213/)

<a id="topic-2.2.2.1.3-3"></a>

###### Cabazitaxel: FDA-approved indication and TROPIC overall survival

> “JEVTANA® is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.”

Source: [Jevtana prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201023s026lbl.pdf)

| Outcome | Cabazitaxel plus prednisone | Mitoxantrone plus prednisone |
| --- | --- | --- |
| Median survival, months (95% CI) | “15.1 (14.1-16.3)” | “12.7 (11.6-13.7)” |
| Hazard ratio (95% CI) | “0.70 (0.59-0.83)” | Not applicable |

Source: [Jevtana prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201023s026lbl.pdf)

<a id="topic-2.2.2.1.3-4"></a>

###### Cabazitaxel: TROPIC publication

> “At the cutoff for the final analysis (Sept 25, 2009), median survival was 15·1 months (95% CI 14·1-16·3) in the cabazitaxel group and 12·7 months (11·6-13·7) in the mitoxantrone group.”
> “The most common clinically significant grade 3 or higher adverse events were neutropenia (cabazitaxel, 303 [82%] patients vs mitoxantrone, 215 [58%]) and diarrhoea (23 [6%] vs one [<1%]).”

Source: [de Bono et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20888992/)

<a id="topic-2.2.2.1.3-5"></a>

###### Cabazitaxel versus a second androgen receptor pathway inhibitor after docetaxel: CARD

> “in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen and had progressed within 12 months of initiating either abiraterone or enzalutamide.”

Source: [Jevtana prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201023s026lbl.pdf)

| Outcome | Cabazitaxel plus prednisone or prednisolone plus G-CSF | Abiraterone plus prednisone or prednisolone, or enzalutamide |
| --- | --- | --- |
| Median rPFS, months (95% CI) | “8.0 (5.7 to 9.2)” | “3.7 (2.8 to 5.1)” |
| rPFS hazard ratio (95% CI) | “0.54 (0.40 to 0.73)” | Not applicable |
| Median OS, months (95% CI) | “13.6 [11.5; 17.5]” | “11.0 [9.2; 12.9]” |
| OS hazard ratio (95% CI) | “0.64 [0.46; 0.89]” | Not applicable |

Source: [Jevtana prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201023s026lbl.pdf)

<a id="topic-2.2.2.1.3-6"></a>

###### Cabazitaxel versus a second androgen receptor pathway inhibitor: CARD publication

> “Adverse events of grade 3 or higher occurred in 56.3% of patients receiving cabazitaxel and in 52.4% of those receiving an androgen-signaling-targeted inhibitor.”
> “tumor response was noted in 36.5% and 11.5% (P = 0.004)”

Source: [de Wit et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31566937/)

<a id="topic-2.2.2.1.3-7"></a>

###### Guideline statements on chemotherapy after androgen receptor pathway inhibitors

> “Offer chemotherapy to patients previously treated with an androgen receptor pathway inhibitor (ARPI).”
> “Offer patients with metastatic castrate-resistant PCa (mCRPC) who are candidates for cytotoxic therapy and are chemotherapy naïve docetaxel with 75 mg/m 2 every three weeks.”
> “Offer cabazitaxel to patients previously treated with docetaxel who have progressed within 12 months of treatment with abiraterone or enzalutamide for mCRPC.”
> “The use of chemotherapy with docetaxel and subsequent cabazitaxel in the treatment sequence is recommended and should be applied early enough when the patient is still fit for chemotherapy.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.3-8"></a>

###### Platinum chemotherapy: guideline treatment-selection factors

> “known histological variants and DNA repair deficiency (to consider platinum or targeted therapy like PARPi);”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.3-9"></a>

###### Carboplatin added to cabazitaxel: randomized phase 2 trial

> “At a median follow-up of 31·0 months (IQR 20·5–37·1), the combination improved the median progression-free survival from 4·5 months (95% CI 3·5–5·7) to 7·3 months (95% CI 5·5–8·2; hazard ratio 0·69, 95% CI 0·50–0·95, p=0·018).”
> “In the phase 2 study, the most common grade 3–5 adverse events were fatigue (7 [9%] of 79 in the cabazitaxel group vs 16 [20%] of 81 in the combination group), anaemia (3 [4%] vs 19 [23%]), neutropenia (3 [4%] vs 13 [16%]), and thrombocytopenia (1 [1%] vs 11 [14%]).”

Source: [Corn et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6858999/)

Additional sources: [AUA (2026)](https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer); [Fizazi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41679466/); [NCCN (2026)](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf); [Annala et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33836265/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 PARP Inhibitors

<a id="topic-2.2.2.1.4-1"></a>

###### Olaparib monotherapy: FDA-approved indication after enzalutamide or abiraterone

> “Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.”

Source: [Lynparza prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208558s031lbl.pdf)

<a id="topic-2.2.2.1.4-2"></a>

###### Olaparib monotherapy: PROfound efficacy, cohort A

| Outcome | Olaparib (n=162) | Enzalutamide or abiraterone acetate (n=83) |
| --- | --- | --- |
| Median rPFS, months (95% CI) | “7.4 (6.2, 9.3)” | “3.6 (1.9, 3.7)” |
| rPFS hazard ratio (95% CI) | “0.34 (0.25, 0.47)” | Not applicable |
| Median OS, months (95% CI) | “19.1 (17.4, 23.4)” | “14.7 (11.9, 18.8)” |
| OS hazard ratio (95% CI) | “0.69 (0.50, 0.97)” | Not applicable |

Source: [Lynparza prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208558s031lbl.pdf)

<a id="topic-2.2.2.1.4-3"></a>

###### Olaparib monotherapy: PROfound primary publication

> “We conducted a randomized, open-label, phase 3 trial evaluating the PARP inhibitor olaparib in men with metastatic castration-resistant prostate cancer who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone).”
> “In cohort A, imaging-based progression-free survival was significantly longer in the olaparib group than in the control group (median, 7.4 months vs. 3.6 months; hazard ratio for progression or death, 0.34; 95% confidence interval, 0.25 to 0.47; P<0.001)”
> “Anemia and nausea were the main toxic effects in patients who received olaparib.”

Source: [de Bono et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32343890/)

<a id="topic-2.2.2.1.4-4"></a>

###### Olaparib monotherapy: PROfound overall survival publication

> “The median duration of overall survival in cohort A was 19.1 months with olaparib and 14.7 months with control therapy (hazard ratio for death, 0.69; 95% confidence interval [CI], 0.50 to 0.97; P = 0.02).”
> “In cohort B, the median duration of overall survival was 14.1 months with olaparib and 11.5 months with control therapy.”
> “Overall, 86 of 131 patients (66%) in the control group crossed over to receive olaparib (56 of 83 patients [67%] in cohort A).”

Source: [Hussain et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32955174/)

<a id="topic-2.2.2.1.4-5"></a>

###### Rucaparib: FDA-approved indication after androgen receptor-directed therapy

> “for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy.”

Source: [Rubraca prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf)

<a id="topic-2.2.2.1.4-6"></a>

###### Rucaparib: TRITON3 efficacy, BRCA-mutated subgroup

| Outcome | Rucaparib (N=201) | Androgen receptor pathway inhibitor or docetaxel (N=101) |
| --- | --- | --- |
| Median rPFS, months (95% CI) | “11.2 (9.2-13.8)” | “6.4 (5.4-8.3)” |
| rPFS hazard ratio (95% CI) | “0.50 (0.36, 0.69)” | Not applicable |
| Median OS, months (95% CI) | “23.2 (19.1, 25.2)” | “21.2 (18.0, 23.1)” |
| OS hazard ratio (95% CI) | “0.91 (0.68, 1.20)” | Not applicable |
| Overall response rate, % (95% CI) | “45.1 (34.1, 56.5)” | “17.1 (7.2, 32.1)” |

Source: [Rubraca prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf)

<a id="topic-2.2.2.1.4-7"></a>

###### Rucaparib: TRITON3 crossover and ATM subgroup

> “In an exploratory analysis in the subgroup of 103 (25%) patients with ATM mutations, the rPFS hazard ratio was 0.95 (95% CI: 0.59, 1.52) and the OS hazard ratio was 1.21 (95% CI: 0.77, 1.90), indicating that the improvement in the overall population was primarily attributed to the results seen in the subgroup of patients with BRCAm.”
> “Of patients with BRCAm who were randomized to receive ARPI or docetaxel (n=101), 52% crossed over to receive RUBRACA after disease progression.”

Source: [Rubraca prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf)

<a id="topic-2.2.2.1.4-8"></a>

###### Rucaparib: TRITON3 comparisons with docetaxel and with a second inhibitor

> “In the BRCA subgroup, the median duration of imaging-based progression-free survival was longer with rucaparib than with docetaxel (11.2 months vs. 8.3 months; hazard ratio, 0.53; 95% CI, 0.37 to 0.77)”
> “the median duration was also longer with rucaparib than with abiraterone acetate or enzalutamide (11.2 months vs. 4.5 months; hazard ratio, 0.38; 95% CI, 0.25 to 0.58)”

Source: [Fizazi et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10064172/)

<a id="topic-2.2.2.1.4-9"></a>

###### Guideline statements on PARP inhibitors in pretreated disease

> “Offer poly(ADP-ribose) polymerase (PARP) inhibitor monotherapy to pre-treated mCRPC patients with relevant DNA repair gene mutations.”
> “In case of a known BRCA alteration, the use of a PARP inhibitor should always be prioritised as these patients harbour an adverse prognosis and don’t respond well to most other treatments.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.4-10"></a>

###### First-line combination in inhibitor-naive disease: olaparib with abiraterone

> “Lynparza is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration- resistant prostate cancer (mCRPC).”
> “Patients with prior treatment with abiraterone were excluded.”

Source: [Lynparza prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208558s031lbl.pdf)

| Outcome (BRCA-mutated subgroup, exploratory) | Olaparib plus abiraterone (N = 47) | Placebo plus abiraterone (N = 38) |
| --- | --- | --- |
| Median rPFS, months (95% CI) | “NR (NR, NR)” | “8 (6, 15)” |
| rPFS hazard ratio (95% CI) | “0.24 (0.12, 0.45)” | Not applicable |
| Median OS, months (95% CI) | “NR (NR, NR)” | “23 (18, 34)” |
| OS hazard ratio (95% CI) | “0.30 (0.15, 0.59)” | Not applicable |

Source: [Lynparza prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208558s031lbl.pdf)

<a id="topic-2.2.2.1.4-11"></a>

###### First-line combination in inhibitor-naive disease: PROpel publication

> “We conducted a double-blind, phase 3 trial of abiraterone and olaparib versus abiraterone and placebo in patients with mCRPC in the first-line setting.”
> “At this planned primary analysis at the first data cutoff, median ibPFS was significantly longer in the abiraterone and olaparib arm than in the abiraterone and placebo arm (24.8 vs. 16.6 months; hazard ratio, 0.66; 95% confidence interval [CI], 0.54 to 0.81; P<0.001)”

Source: [Clarke et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/38319800/)

<a id="topic-2.2.2.1.4-12"></a>

###### First-line combination: talazoparib with enzalutamide

> “metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer with homologous recombination repair (HRR) gene mutations, as detected by an FDA-authorized test”

Source: [Talzenna prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/211651s014lbl.pdf)

| Outcome (TALAPRO-2, HRR gene-mutated) | Talazoparib with enzalutamide (N=200) | Placebo with enzalutamide (N=199) |
| --- | --- | --- |
| Median rPFS by BICR, months (95% CI) | “NR (21.9, NR)” | “13.8 (11.0, 16.7)” |
| rPFS hazard ratio (95% CI) | “0.45 (0.33, 0.61)” | Not applicable |
| Median OS, months (95% CI) | “45.1 (35.4, NR)” | “31.1 (27.3, 35.4)” |
| OS hazard ratio (95% CI) | “0.62 (0.48, 0.81)” | Not applicable |

Source: [Talzenna prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/211651s014lbl.pdf)

<a id="topic-2.2.2.1.4-13"></a>

###### First-line combination: TALAPRO-2 all-comers publication

> “TALAPRO-2 is a randomised, double-blind, phase 3 trial of talazoparib plus enzalutamide versus placebo plus enzalutamide as first-line therapy in men (age ≥18 years [≥20 years in Japan]) with asymptomatic or mildly symptomatic mCRPC receiving ongoing androgen deprivation therapy.”
> “At the planned primary analysis, median rPFS was not reached (95% CI 27·5 months-not reached) for talazoparib plus enzalutamide and 21·9 months (16·6-25·1) for placebo plus enzalutamide (hazard ratio 0·63; 95% CI 0·51-0·78; p<0·0001).”

Source: [Agarwal et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37285865/)

<a id="topic-2.2.2.1.4-14"></a>

###### First-line combination: niraparib with abiraterone acetate

> “AKEEGA with prednisone is indicated for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).”

Source: [Akeega prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216793s001lbl.pdf)

| Outcome (MAGNITUDE, BRCA-mutated subgroup) | Niraparib with abiraterone acetate (N=113) | Placebo with abiraterone acetate (N=112) |
| --- | --- | --- |
| Median rPFS, months (95% CI) | “16.6 (13.9, NE)” | “10.9 (8.3, 13.8)” |
| rPFS hazard ratio (95% CI) | “0.53 (0.36, 0.79)” | Not applicable |

Source: [Akeega prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216793s001lbl.pdf)

<a id="topic-2.2.2.1.4-15"></a>

###### Guideline statements on first-line PARP inhibitor combinations

> “Offer patients previously untreated for mCRPC and harbouring an HRR or breast cancer gene ( BRCA ) mutation abiraterone in combination with olaparib if the patient is fit for both agents and did not previously receive an ARPI.”
> “Offer patients previously untreated for mCRPC and harbouring a BRCA mutation abiraterone in combination with niraparib if the patient is fit for both agents and did not previously receive an ARPI.”
> “Offer patients previously untreated for mCRPC and harbouring an HRR mutation enzalutamide in combination with talazoparib, if the patient is fit for both agents and did not previously receive an ARPI.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

Additional sources: [AUA (2026)](https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer); [Fizazi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41679466/); [NCCN (2026)](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf); [Agarwal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40683290/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 PSMA-targeted Radioligand Therapy

<a id="topic-2.2.2.1.5-1"></a>

###### FDA-approved indication in androgen pathway modulation-resistant prostate cancer

> “PLUVICTO is indicated for the treatment of adult patients with PSMA-positive metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer who have been treated with ARPI therapy, and”
> “are considered appropriate to delay taxane-based chemotherapy, or”
> “have received prior taxane-based chemotherapy.”

Source: [Pluvicto prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215833s037lbl.pdf)

<a id="topic-2.2.2.1.5-2"></a>

###### Patient selection by PSMA positron emission tomography

> “Select patients with metastatic prostate cancer for treatment with PLUVICTO using LOCAMETZ or another approved PSMA positron emission tomography (PET) product based on PSMA expression in tumors.”

Source: [Pluvicto prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215833s037lbl.pdf)

<a id="topic-2.2.2.1.5-3"></a>

###### Taxane-naive disease after one ARPI: trial population and crossover

> “Patients were required to have progressed only once on an ARPI (abiraterone acetate, enzalutamide, darolutamide, or apalutamide).”
> “Patients were considered appropriate for delay of taxane-based chemotherapy by the investigator.”
> “Of patients that were randomized to receive a change in ARPI, 141 patients (60%) crossed over to receive PLUVICTO after confirmation of radiographic disease progression by BICR.”

Source: [Pluvicto prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215833s037lbl.pdf)

<a id="topic-2.2.2.1.5-4"></a>

###### Taxane-naive disease after one ARPI: efficacy versus a change in ARPI

| Outcome | Lutetium Lu 177 vipivotide tetraxetan | Change in ARPI | Hazard ratio (95% CI) |
| --- | --- | --- | --- |
| Radiographic progression-free survival, median months (95% CI) | “9.3 (7, NE)” | “5.6 (4, 6)” | “0.41 (0.29, 0.56)” |
| Overall survival, median months (95% CI) | “24.5 (19.5, 28.9)” | “23.1 (19.6, 25.5)” | “0.91 (0.72, 1.14)” |

Source: [Pluvicto prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215833s037lbl.pdf)

<a id="topic-2.2.2.1.5-5"></a>

###### Taxane-naive disease after one ARPI: updated radiographic progression-free survival and safety

> “In an updated analysis at the third interim overall survival analysis, the HR for rPFS was 0·49 (95% CI, 0·39–0·61; median rPFS, 11·60 months [95% CI, 9·30–14·19] vs 5·59 [4·21–5·95]).”
> “The incidence of grade 3–5 adverse events was lower with 177 Lu-PSMA-617 vs ARPI change (81/227 [36%] vs 112/232 [48%]; grade 3–4, 80/227 [35%] vs 111/232 [48%]).”

Source: [Morris et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12121614/)

<a id="topic-2.2.2.1.5-6"></a>

###### Disease after ARPI and taxane chemotherapy: overall survival versus best standard of care

| Outcome | Lutetium Lu 177 vipivotide tetraxetan plus best standard of care | Best standard of care | Hazard ratio (95% CI) |
| --- | --- | --- | --- |
| Overall survival, median months (95% CI) | “15.3 (14.2, 16.9)” | “11.3 (9.8, 13.5)” | “0.62 (0.52, 0.74)” |

Source: [Pluvicto prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215833s037lbl.pdf)

<a id="topic-2.2.2.1.5-7"></a>

###### Disease after ARPI and taxane chemotherapy: imaging-based progression-free survival and adverse events

> “177 Lu-PSMA-617 plus standard care significantly prolonged, as compared with standard care, both imaging-based progression-free survival (median, 8.7 vs. 3.4 months; hazard ratio for progression or death, 0.40; 99.2% confidence interval [CI], 0.29 to 0.57;”
> “The incidence of adverse events of grade 3 or above was higher with 177 Lu-PSMA-617 than without (52.7% vs. 38.0%), but quality of life was not adversely affected.”

Source: [Sartor et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8446332/)

<a id="topic-2.2.2.1.5-8"></a>

###### Comparison with cabazitaxel after docetaxel

> “The primary endpoint was a reduction of at least 50% in PSA.”
> “The first endpoint was met (66% vs. 37% for 177Lu–PSMA-617 vs. cabazitaxel, respectively, by intention to treat;”
> “Overall survival was similar between randomly assigned patients in the two groups (19.1 vs. 19.6 months; difference -0.5, 95% CI: -3.7 to 2.7]; p = 0.77)”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.5-9"></a>

###### Myelosuppression

> “In the PSMAfore study, Grade 3 or 4 decreased hemoglobin (7%), decreased leukocytes (4.4%), decreased neutrophils (3.5%), and decreased platelets (2.7%) occurred in patients treated with PLUVICTO.”
> “In the VISION study, Grade 3 or 4 decreased hemoglobin (15%), decreased platelets (9%), decreased leukocytes (7%), and decreased neutrophils (4.5%) occurred in patients treated with PLUVICTO.”

Source: [Pluvicto prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215833s037lbl.pdf)

<a id="topic-2.2.2.1.5-10"></a>

###### Guideline recommendations

> “Offer 177Lu-PSMA-617 to ARPI and docetaxel pre-treated mCRPC patients with one or more metastatic lesions, highly expressing prostate-specific membrane antigen (PSMA) on diagnostic radiolabelled PSMA positron emission tomography/computed tomography (PET/CT) scan and lacking any relevant non-PSMA avid metastases.”
> “Offer 177Lu-PSMA-617 to ARPI pre-treated mCRPC patients with one or more metastatic lesions, highly expressing PSMA (exceeding the uptake in the liver) on diagnostic radiolabelled PSMA PET/CT scan, if not fit for docetaxel.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

> “Evidence supports the use of 177Lu-PSMA-617 after taxanes and after androgen therapy.”

Source: [National Cancer Institute Prostate Cancer Treatment PDQ](https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq)

Additional sources: [Hofman et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33581798/); [Hofman et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38043558/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Alpha-emitting Radiopharmaceuticals

<a id="topic-2.2.2.1.6-1"></a>

###### FDA-approved indication and dosing

> “Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.”
> “The dose regimen of Xofigo is 55 kBq (1.49 microcurie) per kg body weight, given at 4 week intervals for 6 injections.”

Source: [Xofigo prescribing information (2019)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203971s016lbl.pdf)

<a id="topic-2.2.2.1.6-2"></a>

###### Symptomatic bone-metastatic disease: trial population

> “Patients with visceral metastases and malignant lymphadenopathy exceeding 3 cm were excluded.”
> “Prior bisphosphonates were used by 41% of patients and 58% had received prior docetaxel.”

Source: [Xofigo prescribing information (2019)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203971s016lbl.pdf)

<a id="topic-2.2.2.1.6-3"></a>

###### Symptomatic bone-metastatic disease: overall survival versus placebo

| Analysis | Radium Ra 223 dichloride, median months (95% CI) | Placebo, median months (95% CI) | Hazard ratio (95% CI) |
| --- | --- | --- | --- |
| Interim analysis | “14.0 (12.1, 15.8)” | “11.2 (9.0, 13.2)” | “0.695 (0.552, 0.875)” |
| Updated analysis | “14.9 (13.9, 16.1)” | “11.3 (10.4, 12.8)” | “0.695 (0.581, 0.832)” |

Source: [Xofigo prescribing information (2019)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203971s016lbl.pdf)

<a id="topic-2.2.2.1.6-4"></a>

###### Symptomatic skeletal events

> “The rates of symptomatic skeletal events (33% vs. 38%) and spinal cord compression (4% vs. 7%) were also statistically significantly improved.”

Source: [National Cancer Institute Prostate Cancer Treatment PDQ](https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq)

<a id="topic-2.2.2.1.6-5"></a>

###### Bone marrow suppression

> “In the randomized trial, 2% of patients on the Xofigo arm experienced bone marrow failure or ongoing pancytopenia compared to no patients treated with placebo.”
> “Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression.”

Source: [Xofigo prescribing information (2019)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203971s016lbl.pdf)

<a id="topic-2.2.2.1.6-6"></a>

###### Combination with abiraterone acetate

> “Xofigo is not recommended for use in combination with abiraterone acetate plus prednisone/prednisolone outside of clinical trials.”
> “At the primary analysis, an increased incidence of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received Xofigo in combination with abiraterone acetate plus prednisone/prednisolone compared to patients who received placebo in combination with abiraterone acetate plus prednisone/prednisolone.”

Source: [Xofigo prescribing information (2019)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203971s016lbl.pdf)

<a id="topic-2.2.2.1.6-7"></a>

###### Combination with enzalutamide

> “Radiographic PFS was 16.4 (95% CI 13.8-19.2) months in the ENZ arm and 19.4 (95% CI 17.1-25.3) months in the ENZ-RAD arm.”
> “The HR for OS was 0.69 (95% CI 0.52-0.90; p = 0.0031), with median OS in the preplanned interim analysis of 35.0 (95% CI 28.8-38.9) months in the ENZ arm and 42.3 (95% CI 36.8-49.1) months in the ENZ-RAD arm.”
> “After an amendment, co-administration of zoledronic acid or denosumab (bone protecting agents) was obligatory.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.6-8"></a>

###### Guideline recommendations

> “Offer enzalutamide plus radium-223 to asymptomatic or mildly symptomatic mCRPC patients with bone metastases without visceral metastases.”
> “Due to safety concerns following ARPI combination treatment use of radium-223 was restricted by EMA to after docetaxel and at least one AR targeted agent”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

Additional sources: [Parker et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23863050/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Autologous Cellular Immunotherapy

<a id="topic-2.2.2.1.7-1"></a>

###### FDA-approved indication and dosing

> “PROVENGE is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.”
> “Administer 3 doses at approximately 2-week intervals.”
> “Each dose of PROVENGE requires a standard leukapheresis procedure approximately 3 days prior to the infusion.”

Source: [Provenge prescribing information](https://www.fda.gov/media/78511/download)

<a id="topic-2.2.2.1.7-2"></a>

###### Asymptomatic or minimally symptomatic disease: trial population

> “Exclusion criteria included visceral (liver, lung, or brain) metastases, moderate to severe prostate cancer-related pain, and use of narcotics for cancer-related pain.”
> “Forty-eight percent of patients were receiving bisphosphonates and 18% had received prior chemotherapy, including docetaxel.”

Source: [Provenge prescribing information](https://www.fda.gov/media/78511/download)

<a id="topic-2.2.2.1.7-3"></a>

###### Asymptomatic or minimally symptomatic disease: overall survival versus control

| Study | Sipuleucel-T, median months (95% CI) | Control, median months (95% CI) | Hazard ratio | Hazard ratio 95% CI |
| --- | --- | --- | --- | --- |
| Study 1 | “25.8 (22.8, 27.7)” | “21.7 (17.7, 23.8)” | “0.775” | “(0.614, 0.979)” |

Source: [Provenge prescribing information](https://www.fda.gov/media/78511/download)

> “After a median follow-up of 34.1 months, the overall mortality was 61.6% in the sipuleucel-T group versus 70.8% in the placebo group (HRdeath, 0.78; 95% CI, 0.61–0.98;”
> “However, the improved survival was not accompanied by measurable antitumor effects.”

Source: [National Cancer Institute Prostate Cancer Treatment PDQ](https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq)

<a id="topic-2.2.2.1.7-4"></a>

###### Time to disease progression

> “Analyses of time to disease progression did not meet statistical significance in any Phase 3 study of PROVENGE.”

Source: [Provenge prescribing information](https://www.fda.gov/media/78511/download)

<a id="topic-2.2.2.1.7-5"></a>

###### Acute infusion reactions

> “In controlled clinical trials, severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group.”

Source: [Provenge prescribing information](https://www.fda.gov/media/78511/download)

Additional sources: [Kantoff et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20818862/)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Immune Checkpoint Inhibitors

<a id="topic-2.2.2.1.8-1"></a>

###### FDA-approved tumor-agnostic indications

> “KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options”
> “KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥13 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test”

Source: [Keytruda prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.8-2"></a>

###### MSI-H or dMMR solid tumors: objective response in prostate cancer

| Tumor type | Patients | Objective response, n (%) | 95% CI | Duration of response, months |
| --- | --- | --- | --- | --- |
| Prostate cancer | “8” | “1 (13%)” | “(0%, 53%)” | “24.5+” |

Source: [Keytruda prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.8-3"></a>

###### Prevalence of MSI-H or dMMR prostate cancer and response to PD-1 or PD-L1 blockade

> “Among the 1033 patients who had adequate tumor quality for MSIsensor analysis (mean [SD] age, 65.6 [9.3] years), 32 (3.1%) had MSI-H/dMMR prostate cancer.”
> “Eleven patients with MSI-H/dMMR castration-resistant prostate cancer received anti–PD-1/PD-L1 therapy.”
> “Six of these (54.5%) had a greater than 50% decline in prostate-specific antigen levels, 4 of whom had radiographic responses.”

Source: [Abida et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6459218/)

<a id="topic-2.2.2.1.8-4"></a>

###### Pembrolizumab monotherapy in biomarker-unselected disease after docetaxel and endocrine therapy

> “Cohorts 1 and 2 enrolled patients with RECIST-measurable PD-L1–positive and PD-L1–negative disease, respectively.”
> “Objective response rate was 5% (95% CI, 2% to 11%) in cohort 1 and 3% (95% CI, < 1% to 11%) in cohort 2.”
> “Median OS was 9.5 months in cohort 1, 7.9 months in cohort 2, and 14.1 months in cohort 3.”

Source: [Antonarakis et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7186583/)

<a id="topic-2.2.2.1.8-5"></a>

###### Combination with docetaxel

> “So far, no combination with docetaxel has proven to be superior to docetaxel alone in unselected mCRPC patients, including the combination with the checkpoint inhibitor pembrolizumab”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.8-6"></a>

###### Guideline statements on biomarker testing

> “Microsatellite instability (MSI) high (or MMR deficiency) is rare in PCa, but for those patients, pembrolizumab has been approved by the FDA and could be a valuable additional treatment option”
> “Offer mCRPC patients somatic and/or germline molecular testing, as well as testing for mismatch repair deficiencies or microsatellite instability, if not done previously.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Bone-targeted Agents

<a id="topic-2.2.2.1.9-1"></a>

###### FDA-approved indications

> “Xgeva is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.”

Source: [Xgeva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125320s225lbl.pdf)

> “Zometa is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy.”
> “Prostate cancer should have progressed after treatment with at least one hormonal therapy.”

Source: [Zometa prescribing information (2018)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021223s041lbl.pdf)

<a id="topic-2.2.2.1.9-2"></a>

###### Denosumab versus zoledronic acid in castration-resistant disease with bone metastases

> “Median time to first on-study skeletal-related event was 20·7 months (95% CI 18·8–24·9) with denosumab compared with 17·1 months (15·0–19·4) with zoledronic acid (hazard ratio 0·82, 95% CI 0·71–0·95; p=0·0002 for non-inferiority; p=0·008 for superiority).”
> “More events of hypocalcaemia occurred in the denosumab group (121 [13%]) than in the zoledronic acid group (55 [6%]; p<0·0001).”
> “Osteonecrosis of the jaw occurred infrequently (22 [2%] vs 12 [1%]; p=0·09).”

Source: [Fizazi et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3090685/)

> “Overall survival and progression-free survival were similar between arms in all three trials.”

Source: [Xgeva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125320s225lbl.pdf)

<a id="topic-2.2.2.1.9-3"></a>

###### Zoledronic acid versus placebo in metastatic prostate cancer

| Study | Patients with a skeletal-related event, zoledronic acid 4 mg | Patients with a skeletal-related event, placebo | Median days to first skeletal-related event, zoledronic acid 4 mg | Median days to first skeletal-related event, placebo | Hazard ratio for first skeletal-related event (95% CI) |
| --- | --- | --- | --- | --- | --- |
| Prostate cancer study | “33%” | “44%” | “Not Reached” | “321” | “0.67 (0.49, 0.91)” |

Source: [Zometa prescribing information (2018)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021223s041lbl.pdf)

> “No survival benefit has been seen in any prospective trial with bisphosphonates.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.9-4"></a>

###### Osteonecrosis of the jaw and hypocalcemia

> “In the primary treatment phases of Studies 20050136, 20050244, and 20050103, ONJ was confirmed in 1.8% of patients in the Xgeva group (median exposure of 12.0 months; range: 0.1-41) and 1.3% of patients in the zoledronic acid group.”

Source: [Xgeva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125320s225lbl.pdf)

> “The potential toxicity (e.g. osteonecrosis of the jaw, hypocalcaemia) of these drugs must always be kept in mind (5–8.2% in M0 CRPC and mCRPC, respectively)”
> “Daily calcium (> 500 mg) and vitamin D (> 400 IU equivalent) are recommended in all patients, except in case of hypercalcaemia”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.9-5"></a>

###### Bone protection during ARPI and radium-223 treatment

> “For patients who received bone protecting agent (BPA) therapy, after it became mandatory on the trial, fracture rates significantly decreased in both study arms one-year fractures decreased from 15.6% to 2.6% with a BPA in patients receiving enzalutamide monotherapy.”
> “This underscores the high risk of fracture in patients with mCRPC and the necessity of complying with guidelines regarding BPA administration in the ARPI era”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

Additional sources: [Saad et al. (2002)](https://pubmed.ncbi.nlm.nih.gov/12359855/); [Saylor et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31990618/)

<a id="heading-2.2.2.1.10"></a>

###### 2.2.2.1.10 Limitations of Current Therapies

<a id="topic-2.2.2.1.10-1"></a>

###### Summary

- All patients treated for mCRPC eventually progress. The EAU guideline advises avoiding sequencing of androgen receptor-targeted agents, citing cross-resistance that it extends from abiraterone to apalutamide and darolutamide.
- Activity of a second ARPI is limited. In a randomized crossover trial, PSA responses to second-line therapy occurred in 26 of 73 participants (36%) receiving enzalutamide and 3 of 75 (4%) receiving abiraterone. In a single-arm study of enzalutamide after at least 24 weeks of abiraterone, median radiographic progression-free survival (rPFS) was 8.1 months and the unconfirmed PSA response rate was 27% (48 of 181). In PLATO, adding abiraterone after PSA progression on enzalutamide did not prolong progression-free survival (5.7 vs 5.6 months; HR, 0.83; 95% CI, 0.61 to 1.12).
- In the control arms of randomized trials, median rPFS with a second ARPI was 3.7 months in CARD (after docetaxel), 3.6 months in PROfound cohort A (homologous recombination repair gene alterations), 4.5 months in the TRITON3 BRCA subgroup, and 5.59 months in PSMAfore (taxane-naive, third data cut-off), where 17% had a confirmed PSA decline of at least 50%. These figures are cross-trial. The PSMAfore investigators stated that a change in ARPI “has lesser clinical efficacy than taxanes”.
- Second ARPIs are nonetheless common in practice. In Medicare claims, novel hormonal therapy followed by a different novel hormonal therapy was the most common first- to second-line sequence (33%), only 28% of men starting first-line novel hormonal therapy later received a different class, and 22% received no life-prolonging therapy after mCRPC diagnosis.
- Taxane chemotherapy carries toxicity: the cabazitaxel label reports serious adverse reactions in 39% of recipients and neutropenic deaths, and in CARD treatment discontinuations for adverse reactions occurred in 20% of cabazitaxel recipients and 8% of those receiving abiraterone or enzalutamide. In TROPIC, grade 3 or higher neutropenia occurred in 82% of cabazitaxel recipients.
- PSMA-targeted radioligand therapy requires PSMA-positive disease on PET imaging and delivery by providers licensed to handle radiopharmaceuticals; in VISION, 126 screened participants (12.6%) did not meet PSMA imaging criteria. In PSMAfore, median overall survival was 24.5 months with lutetium Lu 177 vipivotide tetraxetan and 23.1 months with a change in ARPI (HR, 0.91; 95% CI, 0.72 to 1.14); the publication reported crossover in 134 of 234 participants (57%) randomized to ARPI change, which “may have confounded” the overall survival analysis, and the label reports crossover in 141 participants (60%).
- Biomarker-directed therapies apply to subsets. Alterations in BRCA2, BRCA1, or ATM were found in 29 of 150 metastatic biopsies (19.3%), rucaparib is labeled only for BRCA-mutated disease, and in the TRITON3 ATM subgroup the rPFS hazard ratio was 0.95 (95% CI, 0.59 to 1.52). First-line PARP inhibitor combinations are recommended only for patients who did not previously receive an ARPI, and the olaparib-abiraterone trial excluded prior abiraterone. Microsatellite instability-high or mismatch repair-deficient disease was found in 32 of 1033 patients (3.1%); pembrolizumab produced a response in 1 of 8 patients with prostate cancer in the tumor-agnostic label, and objective response rates of 5% and 3% in PD-L1-positive and PD-L1-negative cohorts after docetaxel and endocrine therapy.
- Other options have restricted populations: radium-223 is labeled for symptomatic bone metastases without known visceral disease, is not recommended with abiraterone plus prednisone because of more fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%), and caused bone marrow failure or ongoing pancytopenia in 2% of recipients. The sipuleucel-T trial excluded visceral metastases and moderate to severe cancer pain; each of its 3 doses requires leukapheresis, and it did not significantly prolong time to disease progression in any phase 3 study. Bisphosphonates have shown no survival benefit in any prospective trial, and overall survival was similar with denosumab and zoledronic acid.

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment); [Khalaf et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31727538/); [de Bono et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28844372/); [Attard et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6118405/); [de Wit et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31566937/); [Lynparza prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208558s031lbl.pdf); [Fizazi et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10064172/); [Morris et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12121614/); [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/); [Jevtana prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201023s026lbl.pdf); [de Bono et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20888992/); [Sartor et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8446332/); [Pluvicto prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215833s037lbl.pdf); [Robinson et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4484602/); [Rubraca prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf); [Abida et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6459218/); [Keytruda prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf); [Antonarakis et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7186583/); [Xofigo prescribing information (2019)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203971s016lbl.pdf); [Provenge prescribing information](https://www.fda.gov/media/78511/download); [Xgeva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125320s225lbl.pdf)

<a id="topic-2.2.2.1.10-2"></a>

###### Progression on available treatments

> “All patients who receive treatment for mCRPC will eventually progress.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.10-3"></a>

###### Cross-resistance between androgen receptor pathway inhibitors

> “In general, sequencing of ARPIs like abiraterone and enzalutamide is not recommended particularly if the time of response to ADT and to the first ARPI was short (≤ six to twelve months) and high-risk features of rapid progression are present”
> “Avoid sequencing of androgen receptor-targeted agents.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.10-4"></a>

###### Radiographic progression-free survival with a change in ARPI

> “A change in ARPI has lesser clinical efficacy than taxanes,”
> “median rPFS in the ARPI change group was 5·59 months at third data cut-off”

Source: [Morris et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12121614/)

<a id="topic-2.2.2.1.10-5"></a>

###### Use of sequential ARPI therapy in place of chemotherapy

> “However, real-world data indicates that many patients do not receive taxane-based chemotherapy after progression on a first ARPI and instead switch to a second ARPI.”

Source: [Morris et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12121614/)

> “The most common 1 L to 2 L treatment sequences among men with ≥2 lines were NHT followed by a different NHT (33%), chemotherapy followed by NHT (14%), and NHT followed by chemotherapy (13%).”
> “For those initiating 1 L treatment with NHTs, only 28% received subsequent treatment with a different class of therapy.”

Source: [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/)

<a id="topic-2.2.2.1.10-6"></a>

###### Toxicity of taxane chemotherapy after ARPI

> “Neutropenic deaths have been reported.”
> “Serious adverse reactions occurred in 39% of patients receiving JEVTANA.”
> “Treatment discontinuations due to adverse drug reactions occurred in 20% of patients who received JEVTANA and 8% of patients who received abiraterone acetate plus prednisone/prednisolone or enzalutamide.”

Source: [Jevtana prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201023s026lbl.pdf)

<a id="topic-2.2.2.1.10-7"></a>

###### Eligibility and delivery requirements for PSMA-targeted radioligand therapy

> “The eligibility criteria for PSMA imaging were not met in 126 patients (12.6%; those with no PSMA-positive lesions or ≥1 exclusionary PSMA-negative lesion) and were met in 869 patients (86.6%; those with ≥1 PSMA-positive lesion and no exclusionary PSMA-negative lesions);”

Source: [Sartor et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8446332/)

> “Radiopharmaceuticals, including PLUVICTO, should be used by or under the control of healthcare providers who are qualified by specific training and experience in the safe use and handling of radiopharmaceuticals, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radiopharmaceuticals.”

Source: [Pluvicto prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215833s037lbl.pdf)

<a id="topic-2.2.2.1.10-8"></a>

###### Overall survival with radioligand therapy before taxane chemotherapy

> “The high crossover rate (134/234 patients [57%] randomised to ARPI change) may have confounded the analysis of overall survival.”

Source: [Morris et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12121614/)

<a id="topic-2.2.2.1.10-9"></a>

###### Eligibility for homologous recombination repair-directed therapy

> “If aberrations of BRCA2, BRCA1 and ATM all confer enhanced sensitivity to PARP inhibitors, 29/150 (19.3%) of mCRPC affected individuals would be predicted to benefit from this therapy.”

Source: [Robinson et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4484602/)

<a id="topic-2.2.2.1.10-10"></a>

###### Eligibility for checkpoint inhibitor therapy

> “The microsatellite instability–high/mismatch repair deficient phenotype is uncommon but clinically important in prostate cancer and can be somatically acquired during disease evolution.”

Source: [Abida et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6459218/)

<a id="topic-2.2.2.1.10-11"></a>

###### Undertreatment in routine practice

> “22% received no life-prolonging therapy after mCRPC, 78% received ≥1 line of therapy (LOT), 42% underwent ≥2 LOTs, and 20% had ≥3 LOTs.”
> “These data highlight the dramatic undertreatment that occurs for mCRPC patients, particularly for therapies beyond NHTs as well as the common use of sequential NHTs in real-world data.”

Source: [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/)

Additional sources: [Fizazi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41679466/); [AUA (2026)](https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

Rinzimetostat is investigational; ORIC has not submitted for or obtained regulatory approval for any product candidate. Himalayas-1 (NCT07723248) is a global, randomized, open-label phase 3 trial of rinzimetostat plus darolutamide compared with a prespecified physician’s choice of an ARPI or docetaxel in approximately 600 participants with mCRPC previously treated with abiraterone. The trial requires disease progression on abiraterone in the metastatic castration-sensitive or first-line mCRPC setting, permits docetaxel for castration-sensitive disease, and excludes prior cytotoxic chemotherapy otherwise, radioligand therapy, and apalutamide, darolutamide, or enzalutamide; it was recruiting with an actual start of 2026-08-03 and an estimated primary completion of 2028-03. The proposed position is therefore after abiraterone and before chemotherapy, radioligand therapy, or a second ARPI for castration-resistant disease. A separate phase 3 trial evaluates another PRC2 inhibitor, mevrometostat, plus enzalutamide against physician’s choice of enzalutamide or docetaxel in mCRPC after at least 12 weeks of abiraterone.

Both components of the regimen are oral: participants are randomized 1:1 to rinzimetostat 400 mg once daily plus darolutamide 600 mg twice daily, while the docetaxel control is given at 75 mg/m2 intravenously every 21 days for up to 10 cycles. The darolutamide label lists non-metastatic castration-resistant and metastatic castration-sensitive prostate cancer (alone or with docetaxel), without mCRPC, and requires a concurrent gonadotropin-releasing hormone agonist or antagonist or prior bilateral orchiectomy.

ORIC estimated the U.S. population at approximately 17,000 men per year with mCRPC previously treated with abiraterone and an addressable market of more than $3.5 billion, reported that abiraterone, the leading ARPI, has maintained more than 50% market share of new prescriptions over the last five years, and stated that this market “lacks oral, well-tolerated therapies with meaningful efficacy”. ORIC is also exploring rinzimetostat in other populations, including post-AR inhibitor mCRPC, and lists a second phase 3 trial (Himalayas-2) with apalutamide. These are company statements that are not peer reviewed.

The regimen pairs rinzimetostat with a second ARPI in a setting where the EAU guideline advises avoiding sequencing of androgen receptor-targeted agents, recommends chemotherapy after an ARPI, and states that an ARPI-ARPI sequence “should never be the preferred option”. In U.S. practice, a second ARPI is nonetheless the most frequent choice: 459 of 804 ARPI-experienced patients with mCRPC (57.1%) received another ARPI and 192 (23.9%) chemotherapy; among 1,519 Medicare patients with prior novel hormonal therapy, 70% received novel hormonal therapy as first-line mCRPC treatment, 7% chemotherapy, and 13% no subsequent life-prolonging therapy. In another real-world cohort, 48.4% received a sequential ARPI and 35% docetaxel as index therapy, abiraterone followed by docetaxel (16.1%) and abiraterone followed by enzalutamide (10.9%) were the most common sequences, and taxane use was 42% to 46% with ECOG performance status 0 to 1 and 29% with ECOG 2 or higher. The initial ARPI is increasingly given before castration resistance: in pre-mCRPC settings in 82.6% of patients in that cohort, and as ARPI-only treatment before mCRPC diagnosis in 34.8% of a U.S. cohort in 2023, compared with 10.3% in 2018.

Source: [ORIC Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330631/oric-20260630.htm); [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf); [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248); [Shore et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13203012/); [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf); [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/); [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm); [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment); [Narayan et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39232487/); [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/); [von Amsberg et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41807148/); [Swami et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42235146/)

<a id="topic-2.2.2.2-2"></a>

###### Proposed position after abiraterone and before chemotherapy for castration-resistant disease

> “Himalayas-1 (NCT07723248) is a global, randomized, open-label Phase 3 study evaluating rinzimetostat plus darolutamide versus a prespecified physician’s choice of ARPI or docetaxel control in approximately 600 patients with mCRPC previously treated with abiraterone”
> “Prior abiraterone in mCSPC or mCRPC setting”
> “May have received docetaxel in mCSPC setting”
> “Prior systemic anticancer therapy, beyond protocol-permitted abiraterone-based treatment and docetaxel in the mCSPC setting”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="topic-2.2.2.2-3"></a>

###### Oral once-daily regimen compared with oral and intravenous control therapies

> “Rinzimetostat is an oral, potent, selective allosteric inhibitor of PRC2”
> “Patients will be randomized 1:1 to receive rinzimetostat 400 mg QD plus darolutamide 600 mg BID, or prespecified physician’s choice of control (ARPI or docetaxel)”
> “Patients randomized to docetaxel will receive 75 mg/m2 intravenously every 21 days for up to 10 cycles”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

> “Recommended Dosage: NUBEQA 600 mg orally twice daily.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.2.2.2-4"></a>

###### Darolutamide labeled indications do not include metastatic castration-resistant disease

> “NUBEQA is indicated for the treatment of adult patients with: • non-metastatic castration resistant prostate cancer (nmCRPC) • metastatic castration-sensitive prostate cancer (mCSPC) • metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.2.2.2-5"></a>

###### Company statement of the anticipated population and unmet need

> “In the US, the annual incidence of mCRPC patients previously treated with abiraterone is approximately 17,000, with an estimated addressable market of greater than $3.5 billion and total global addressable market of $7 billion.”
> “This market lacks oral, well-tolerated therapies with meaningful efficacy.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

> “Abiraterone remains the leading ARPI, maintaining >50% market share of new prescriptions over the last five years”
> “Post-abiraterone mCRPC is a large addressable market with limited effective therapeutic options that are oral and well-tolerated”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.2.2.2-6"></a>

###### Further populations under evaluation by the company

> “Rinzimetostat Is Being Explored in Other Patient Populations that Could Form the Basis of Future Phase 3 Trials, Including Post-AR Inhibitor mCRPC”
> “Rinzimetostat has the potential to address ~70,000 patients in the US with prostate cancer annually”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.2.2.2-7"></a>

###### Guideline position of androgen receptor pathway inhibitor sequencing and chemotherapy

> “Avoid sequencing of androgen receptor-targeted agents.”
> “Offer chemotherapy to patients previously treated with an androgen receptor pathway inhibitor (ARPI).”
> “An ARPI-ARPI sequence should never be the preferred option but might be considered in such patients if the PS still allows for active treatment and the potential side effects seem manageable.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.2-8"></a>

###### US real-world treatment after a prior androgen receptor pathway inhibitor

> “Among 804 ARPI-experienced mCRPC patients, 459 patients (57.1%) received another ARPI as their index therapy and 192 (23.9%) received chemotherapy as their index therapy.”
> “In this real-world analysis, more than half of patients attempted at least 1 additional ARPI in the mCRPC setting, despite prior treatment with ARPIs.”

Source: [Narayan et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39232487/)

> “The most common 1 L to 2 L treatment sequences among men with ≥2 lines were NHT followed by a different NHT (33%), chemotherapy followed by NHT (14%), and NHT followed by chemotherapy (13%).”
> “For those initiating 1 L treatment with NHTs, only 28% received subsequent treatment with a different class of therapy.”
> “Among patients with baseline NHT use (1,519 patients), 70% received 1 L NHT after mCRPC diagnosis, 7% chemotherapy, 6% combination & other, 2% sipuleucel-T, 1% radium-223, and 13% had no subsequent life-prolonging therapy.”

Source: [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/)

> “As index line, most patients received another (sequential) ARPI (48.4%) or docetaxel (35%). Most common sequences from preindex to index therapy were abiraterone→docetaxel (16.1%) and abiraterone→enzalutamide (10.9%).”
> “Patients with ECOG score 0-1 more commonly received taxane therapy (42%-46%) than those with ECOG score ≥ 2 (29%).”

Source: [von Amsberg et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41807148/)

<a id="topic-2.2.2.2-9"></a>

###### Shift of androgen receptor pathway inhibitor use into castration-sensitive disease

> “The use of ARPi-only treatment before mCRPC diagnosis rose from 10.3% in 2018 to 34.8% in 2023.”
> “Over the study course, the majority (76.8%) of patients received an ARPi as 1L treatment for mCRPC.”

Source: [Swami et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42235146/)

> “Initial ARPI was received in pre-mCRPC settings in 82.6% patients and as first-line mCRPC treatment in 17.4%.”

Source: [von Amsberg et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41807148/)

> “Ten per cent of patients had undergone NHT use prior to their mCRPC diagnosis, and 3% had previously been treated with taxane-based chemotherapy.”

Source: [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/)

<a id="topic-2.2.2.2-10"></a>

###### Competing PRC2 inhibitor combination in the same treatment position

> “evaluate mevrometostat plus enzalutamide versus physician’s choice of either enzalutamide or docetaxel in patients with mCRPC who have progressed following ≥12 weeks of treatment with abiraterone”

Source: [Shore et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13203012/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Himalayas-1 stratification factors

> “Randomization will be stratified by prior docetaxel use in the metastatic castration-sensitive prostate cancer (mCSPC) setting, prespecified control category (ARPI versus docetaxel), and presence of hepatic metastases”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="topic-2.2.2.3-2"></a>

###### Liver metastases and overall survival in castration-resistant disease

> “Men with liver metastases had the worst median OS (13.5 months).”
> “In summary, men with mCRPC treated with docetaxel who have liver metastases had worse OS duration than men with lung metastases.”

Source: [Halabi et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872320/)

<a id="topic-2.2.2.3-3"></a>

###### Phase 1b landmark radiographic progression-free survival by prior therapy

| Cohort (rinzimetostat 400 mg once daily plus darolutamide) | Landmark rPFS at 3, 4, and 5 months | Median follow-up |
| --- | --- | --- |
| Previously treated with abiraterone | “93%, 84%, and 84% at 3, 4, and 5 months” | “4.9 months” |
| Previously treated with AR inhibitors | “93%, 85%, and 85% at 3, 4, and 5 months” | “4.8 months” |

Source: [ORIC Pharmaceuticals first quarter results (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-first-quarter-2026-financial-results-and-operational-updates/)

<a id="topic-2.2.2.3-4"></a>

###### Phase 1b safety in the broader post-ARPI population

> “In a broader dataset of post-ARPI (androgen receptor pathway inhibitor) patients (n=72, inclusive of the post-abiraterone patients), the safety and tolerability profile was consistent with the post-abiraterone cohort.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="topic-2.2.2.3-5"></a>

###### Phase 1b ctDNA responses by androgen receptor genotype and partner agent

> “ctDNA molecular responses across a breadth of genotypes including AR mutations, AR amplified, AR wildtype”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

> “Rapid and deep ctDNA responses across a breadth of AR mutations and other gene alterations, with 76% of patients (13/17) achieving >50% ctDNA reduction.”
> “PSA responses and ctDNA reductions were observed across all ORIC-944 dose levels and were also observed at comparable rates in combination with apalutamide or with darolutamide.”

Source: [ORIC Pharmaceuticals dose exploration completion release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-completion-of-dose-exploration-portion-of-oric-944-phase-1b-clinical-trial-and-continues-to-demonstrate-potential-best-in-class-efficacy-and-safety/)

<a id="topic-2.2.2.3-6"></a>

###### Prior androgen receptor pathway inhibitor exposure and outcomes with an ARPI versus cabazitaxel

> “Prior ARPI exposure (in 37.7%) predicted inferior outcomes on ARPIs but not on cabazitaxel.”
> “A high baseline ctDNA fraction correlated with reduced rPFS and OS; plasma AR copy number status was not associated with outcomes, but PTEN alterations were linked with shorter OS (hazard ratio: 1.9, multivariable p = 0.02).”

Source: [Parekh et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41033927/)

<a id="topic-2.2.2.3-7"></a>

###### Duration of response to the first androgen receptor pathway inhibitor

> “In patients who had a short response to the first ARPI for mCRPC (< twelve months), this sequence should be avoided because of known cross resistance and the availability of chemotherapy and PARP inhibitors (if a relevant mutation is present).”
> “In highly selected patients treated for more than 24 weeks with AAP, the sequence with enzalutamide showed some activity with a median rPFS of 8.1 months (95% CI: 6.1–8.3) and an unconfirmed PSA response rate of 27%”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.3-8"></a>

###### Circulating tumor DNA fraction as a prognostic and predictive factor

> “Baseline circulating tumour DNA (ctDNA) fraction above the cohort median and on-treatment ctDNA increase were associated with shorter time to progression (HR = 2.38, P < 0.001; HR = 4.03, P < 0.001).”
> “ctDNA abundance was prognostic independent of clinical features, and holds promise as a stratification biomarker.”

Source: [Annala et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33836265/)

> “a low pretreatment circulating tumor DNA (ctDNA) fraction predicted a superior biochemical response (100% versus 58%, P = 0.0067)”

Source: [Kwan et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40425844/)

<a id="topic-2.2.2.3-9"></a>

###### Outcomes by treatment received before castration resistance

> “In the overall population, median TTPD was 12.1 months and trended lower for patients who had received prior ARPi-only treatment.”
> “Overall median OS was 24.6 months and trended lower for patients who received prior ARPi only or both prior ARPi and taxane.”

Source: [Swami et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42235146/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Multidisciplinary team management

> “Counsel, manage and treat patients with metastatic CRPC (mCRPC) in a multidisciplinary team.”
> “A multidisciplinary approach is required with input from urologists, medical oncologists, radiation oncologists, nurses, psychologists and social workers”
> “Critical issues of palliation must be addressed when considering additional systemic treatment, including management of pain, constipation, anorexia, nausea, fatigue and depression.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.4-2"></a>

###### Germline and somatic genomic testing

> “Patients with metastatic prostate cancer should undergo both germline and somatic DNA sequencing using panel-based assays.”
> “this panel recommends considering retesting in patients whose results were previously negative or uninformative, and to consider either a metastatic biopsy or ctDNA when a significant change in clinical status occurs.”

Source: [Yu et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39787437/)

> “Offer mCRPC patients somatic and/or germline molecular testing, as well as testing for mismatch repair deficiencies or microsatellite instability, if not done previously.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.4-3"></a>

###### Confirmed castrate testosterone and continued androgen deprivation

> “Ensure that testosterone levels are confirmed to be < 50ng/dL before diagnosing castrate-resistant PCa (CRPC).”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

> “Patients receiving NUBEQA should also receive a gonadotropin-releasing hormone (GnRH) agonist or antagonist concurrently or have had a bilateral orchiectomy.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.2.2.4-4"></a>

###### Baseline assessment and monitoring during treatment

> “Baseline examinations should include a medical history, clinical examination, as well as baseline blood tests (PSA, total testosterone level, full blood count, renal function, baseline liver function tests, alkaline phosphatase), bone scan and CT of chest, abdomen and pelvis”
> “Prostate-specific antigen alone is not reliable enough”
> “for monitoring disease activity in advanced CRPC, since visceral metastases may develop in men without rising PSA”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.4-5"></a>

###### Bone health with bone-targeted agents

> “This underscores the high risk of fracture in patients with mCRPC and the necessity of complying with guidelines regarding BPA administration in the ARPI era”
> “Patients should have a dental examination before starting therapy, as the risk of jaw necrosis is increased by several risk factors including a history of trauma, dental surgery or dental infection”
> “Hypocalcaemia must be avoided by adequate intake of calcium and vitamin D before initiating therapy”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

Additional sources: [Fizazi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41679466/); [Saylor et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31990618/); [Giri et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40239123/); [NCCN (2026)](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Himalayas-1 objective and endpoints

> “Himalayas-1 is evaluating whether rinzimetostat plus darolutamide improves outcomes compared with physician’s choice of an ARPI or docetaxel in patients with mCRPC previously treated with abiraterone”
> “The primary endpoint is radiographic progression-free survival (rPFS), with overall survival (OS) as the key secondary endpoint”
> “OS will be formally tested only if the primary rPFS analysis is statistically significant”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="topic-2.2.2.7-2"></a>

###### Company-stated therapeutic goal

> “Combining rinzimetostat with darolutamide may limit tumor cell adaptation and prolong clinical benefit from continued androgen receptor pathway inhibition”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

> “the initiation of our Himalayas-1 Phase 3 trial represents an important milestone toward establishing rinzimetostat as a potentially practice-changing therapy for patients”

Source: [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/)

<a id="topic-2.2.2.7-3"></a>

###### Company benchmark for approved post-ARPI therapies

> “For reference, the 5-month landmark rPFS for these approved therapies ranges from approximately 60% to 75%.”

Source: [ORIC Pharmaceuticals first quarter results (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-first-quarter-2026-financial-results-and-operational-updates/)

> “PRC2 inhibitors in combination with an AR inhibitor have demonstrated much longer rPFS (key regulatory primary endpoint) than what has been reported with other approved and emerging therapies”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.2.2.7-4"></a>

###### Control-arm outcomes with an alternative ARPI or docetaxel after a first ARPI

> “In the control arm of the contemporary PSMAfore trial, the ARPI-switch showed an rPFS of 5.59 months (4.21–5.95)”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

> “employed physician’s choice of docetaxel or second-generation ARPI as the control, and reported an imaging-based PFS of 6.4 months in the control group”

Source: [Shore et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13203012/)

<a id="topic-2.2.2.7-5"></a>

###### US real-world outcomes after a prior androgen receptor pathway inhibitor

> “In the overall population, median time on the index therapy and median time from index therapy to next therapy were 4.1 and 6.2 months, respectively. Median overall survival and radiographic progression-free survival from the initiation of index therapy were 15.1 and 7.0 months, respectively.”

Source: [Narayan et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39232487/)

> “Median time from start of 1 L to next LOT or end of follow-up was 13.7 months, 10.9 months from 2 L start, and 8.9 months from 3 L start.”
> “Median survival was 25.6 months after mCRPC and 23.4 months following treatment initiation.”

Source: [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
